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YBX3 the gene encoding Y box binding protein 3 (=CSDA). 
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ABSTRACT 
Nemaline myopathy (NM) and related disorders constitute a heterogeneous group of 
congenital myopathies. Mutations in the nebulin gene (NEB) are the main cause of the 
recessively inherited form. NEB is one of the largest genes in the human genome 
consisting of 249 kb of genomic sequence. NEB contains 183 exons and a 32 kb 
homologous triplicate region (TRI) where eight exons are repeated three times.  
The aims of this Doctoral Thesis study were to develop and implement into diagnostics 
new efficient variant analysis methods for NEB and other NM-causing genes. The first 
aim was to design and validate a custom copy number microarray targeting the NM-
causing genes for the detection of copy number variations. MLPA (multiplex ligation-
dependent probe amplification) and Sanger sequencing were also used. The second aim 
was to utilise whole-exome sequencing to search for novel disease-causing variants in 
the known NM genes and try to identify novel NM genes. Lastly, the aim was to collect 
more data in order to try to find genotype-phenotype correlations of NEB-caused NM. 
The design and validation of the NM-CGH microarray was successful. Of the total sample 
cohort of 356 NM families, 196 NM families were studied using the custom-made NM-
CGH array. Nine different novel large causative variants were identified in ten NM 
families. The size of these variants varies greatly, covering only a part of one NEB exon 
on up to dozens of NEB exons (72bp - 133 kb). In addition, a novel recurrent variation of 
the NEB TRI region was identified in 13% of the NM families and in 10% of the studied 
60 control samples. Deviations of one copy are suggested to be benign but gains of two 
or more copies might be pathogenic. One novel homozygous deletion was also identified 
in another NM gene, TPM3, in a patient with severe NM. Furthermore, ten samples were 
studied using exome sequencing, and for six of those samples, novel disease-causing 
variant(s) were identified. Two variants were identified in one family in a novel, putative 
NM gene that is currently under further investigation. 
165 NM families from the total cohort of 356 NM families have been identified thus far 
with two pathogenic NEB variants. Altogether 220 different pathogenic variants were 
identified in these 165 families, accentuating that the patients in the majority (84%) of 
the families are compound heterozygous for two different NEB variants. Most of the 
variants are small, containing splice-site mutations (33%), small indels (33%), nonsense 
(22%) and missense mutations (7%). Large variants are the smallest category (5%), 
however, copy number variations are much more frequent than previously thought. 
Genotype-phenotype correlations between the type of NEB mutation and the NM 
subtypes remained, however, unobtainable. 
The NM-CGH microarray has been implemented into molecular diagnostics of NM. Using 
the NM-CGH microarray followed by exome-sequencing has accelerated mutation 
detection. This combination has increased the coverage of the NM genes and thus 
improved the diagnostics of NM and NM-related disorders. 
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TIIVISTELMÄ 
Nemaliinimyopatia (NM) ja samankaltaiset taudit on heterogeeninen tautiryhmä 
synnynnäisten myopatioiden joukossa. Nebuliini-geenin (NEB) mutaatiot ovat yleisin 
resessiivisen NM:n aiheuttaja. NEB on kooltaan 249 kb, eli yksi ihmisen suurimmista 
geeneistä. NEB sisältää 183 eksonia ja se kattaa myös toistojaksoja, kuten homologisen 
triplikaatioalueen (TRI), jossa kahdeksan eksonia toistuu kolme kertaa. 
Väitöskirjatutkimuksen tarkoituksena oli kehittää ja ottaa diagnostiseen käyttöön uusia 
mutaatioanalyysimenetelmiä NEB-geeniä sekä muita NM-geenejä varten. Tavoitteena 
oli suunnitella ja validoida NM-geeneihin kohdennettu mikrosiru, jolla voidaan tutkia 
kopiolukuvariaatioita näistä geeneistä. Lisäksi käytettiin MLPA-menetelmää (multiplex 
ligation-dependent probe amplification) ja Sanger-sekvensointia. Eksomisekvensointia 
hyödynnettiin tautia aiheuttavien varianttien löytämiseksi tunnetuista NM-geeneistä 
sekä uusista geeneistä. Tavoitteena oli lisäksi kerätä lisätietoa nebuliinimutaatioiden 
aiheuttaman nemaliinimyopatian genotyyppi-fenotyyppi -korrelaatiosta. 
NM-CGH-mikrosirun kehittäminen sekä validointi onnistui hyvin. Koko 356 NM-perheen 
näytekohortista 196 perhettä tutkittiin NM-CGH-sirulla, joista tunnistettiin yhteensä 
yhdeksän uutta suurta patogeenistä varianttia kymmenestä eri NM-perheestä. Näiden 
mutaatioiden koko vaihtelee suuresti, kattaen vain osan yhdestä NEB-geenin eksonista 
aina yli puoleen koko geenistä (72 bp – 133 kb). Lisäksi osoitettiin että 13 % tutkituista 
NM-perheistä sekä 10 % tutkituista 60 kontrollinäytteestä sisältää NEB:n triplikaatio-
alueen kopiolukuvariaation. Tutkimustulosten perusteella yhden kopioluvun lisäys tai 
vähenemä olisi harmitonta mutta mikäli ylimääräisiä kopioita on kaksi tai enemmän, se 
voisi olla tautia aiheuttavaa. Lisäksi tunnistettiin homotsygoottinen suuri deleetio 
toisesta tunnetusta NM-geenistä, TPM3. Eksomisekvensoinnilla löydettiin puolestaan 
toinen tai molemmat tautia aiheuttavat variantit kuudelle kymmenestä tutkitusta NM-
potilaasta. Yhdessä NM-perheessä tunnistettiin kaksi uutta varianttia potentiaalisessa 
uudessa NM-geenissä, ja tätä löydöstä tutkitaan parhaillaan tarkemmin. 
Tutkimuskohorttimme 356 NM-perheestä 165 perheelle on nyt tunnistettu kaksi tautia 
aiheuttavaa NEB-varianttia. Näissä perheissä esiintyi yhteensä 220 eri patogeenistä NEB-
varianttia eli suurin osa potilaista (84 %) on yhdistelmäheterotsygootteja. Pääosa 
mutaatioista on splice-site -mutaatioita (33 %), pieniä insertioita tai deleetioita (33 %), 
nonsense- (22 %) ja missense-mutaatioita (7 %). Harvinaisimpia ovat suuret 
kopiolukumuutokset (5 %) mutta näiden osuus on kuitenkin huomattavasti suurempi 
kuin on aiemmin oletettu. NEB-mutaatioiden ja NM-fenotyypin välille ei kuitenkaan 
onnistuttu saamaan genotyyppi-fenotyyppi –korrelaatiota. 
NM-CGH-mikrosirumenetelmä on otettu osaksi nemaliinimyopatian molekyyligeneet-
tistä diagnostiikkaa. NM-CGH-mikrosiruanalyysin ja eksomisekvensoinnin yhdistelmä on 
tehostanut NM-geenien kattavuutta, edistänyt mutaatioiden löytymistä, ja näin ollen 
parantanut nemaliinimyopatian ja muiden samankaltaisten tautien diagnostiikkaa. 
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REVIEW OF THE LITERATURE 
1. Human genome variation 
The human genome consists of a large nuclear genome of 3.1 Gb and a small separate 
mitochondrial genome of 16.6 kb. The ~26 000 genes of the nuclear genome are packed 
into 46 chromosomes that contain 22 autosome pairs and the sex chromosomes, XX for 
females and XY for males. The gene-rich regions of DNA have a high level of methylated 
CpG islands which can be shown as light bands on Giemsa staining (G banding) of 
chromosomes. Protein-coding genes vary greatly in size, differing from <1 kb to >2 Mb. 
The average number of exons in the protein-coding genes is estimated to be 10 but the 
largest genes include more than 300 exons. Most genes also include introns that differ 
greatly in size. However, all genes do not encode proteins but for example pseudogenes 
and retrogenes as well as non-coding RNAs that are involved in protein synthesis, RNA 
maturation, DNA synthesis, gene regulation and transposon control (Lander et al., 2001; 
McPherson et al., 2001; Strachan and Read, 2011; Venter et al., 2001). Altogether, the 
human genome is highly diverse and the various sections and parts have different 
features that are all important for a properly functioning genome.  
It has been estimated that the human genome is approximately 99.5-99.9% identical 
between different individuals. Consequently, the remaining 0.1-0.5% of DNA accounts 
for all individual differences including normal variation and susceptibility to disease 
(Kruglyak and Nickerson, 2001).  
1.1. Normal variation 
1.1.1. Polymorphisms 
Polymorphisms are normal variants in the human genome. Single nucleotide 
polymorphisms (SNPs) are changes of one nucleotide that are found in the general 
population with > 1% frequency. Furthermore, every individual is estimated to carry 
~3 million SNPs in their genome. (Kim et al., 2009; Tong et al., 2010) The database for 
SNPs (dbSNP) hosted by the National Center for Biotechnology Information (NCBI) 
included altogether circa 150 million different SNPs in the human genome (db SNP build 
144 in June 2015).  
Copy number polymorphisms (CNP), also called benign copy number variations, are 
large structural variations. They are benign duplications, deletions or inversions that are 
not known to be associated with a disease or a disorder. Copy number changes have 
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originally been defined as changes of the DNA copy number in a segment of DNA more 
than 1 kb in size (Redon et al., 2006).  The Database of Genomic Variants carries 490 000 
CNPs collected from 67 studies of healthy individuals (July 2015).  
1.1.2. Repetitive DNA 
Human DNA also includes many different types of repetitive sequences; both internal 
and external to gene sequences. The various repeat elements of the human genome can 
be divided into two groups: low-copy repeats (LCR) and high-copy repeats.  
Interspersed repetitive elements are the most common high-copy repeats and they are 
scattered throughout the genome. Moreover, they are estimated to cover ~45% of the 
human genome (Chen et al., 2014; Lander et al., 2001). The most common repetitive 
element in human is the LINE-1 repeat (long interspersed element) that constructs ~17% 
of the human genome. This family is capable of autonomous transposition and still has 
actively transposing members. LINE-1 elements are ~6 kb long elements that encode 
proteins essential for the transposition, such as nucleic acid binding protein and protein 
with endonuclease and reverse transcriptase activities (Beck et al., 2011). Alu repeat 
elements belong to the family of SINE elements (short interspersed elements) and they 
have been named after the AluI restriction site found in their sequence. Alu repeats are 
~280 kb long elements that construct ~10% of the genome. Alu repeats are non-
autonomous transposons that have been shown to use the LINE element machinery for 
transposing (Beck et al., 2011).  
Low-copy repeats (LCR), also known as segmental duplications (SD) compose 
approximately 5% of the human genome. SDs are repeats that occur twice or a few times 
in the genome. SDs are typically 10-300 kb in size, they share 95-97% sequence similarity 
and are usually separated by 50 kb – 10 Mb of intervening sequence (Gu et al., 2008; 
Sharp et al., 2006). 
1.2. Pathogenic variation 
Mutations of DNA occur, for example, in every DNA replication event, but most are 
corrected by cellular DNA repair mechanisms. Mutations that happen in somatic cells 
affect only that individual, but mutations that occur in the gametocytes can be inherited 
by the offspring. Mutations are the major driving force of evolution. The mutation rate 
in the human genome is estimated to be approximately ~1.5 x 10-8 per site per 
generation (Conrad et al., 2011; Lynch, 2010; Samocha et al., 2014). Mutations can 
create modifications of the DNA that enable better adaptation of the individual to the 
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environment. Mutations are more often silent, which means that they do not cause an 
effect on the protein level. However, sometimes mutations can cause adverse effects 
such as a disease. Mutations can be described as heritable changes at the DNA level that 
can cause errors in the gene product, such as proteins that they encode. There are 
different types of mutations that can be categorized, for example based on their size or 
origin. 
1.2.1. Point mutations 
Point mutations alter only one nucleotide of DNA sequence. Depending on the change, 
this can cause an amino acid substitution, a premature stop-codon, abnormal splicing, 
or a silent mutation. A missense mutation causes the encoded amino acid to be 
substituted with another. The change of one amino acid can be harmful if it resides in a 
conserved DNA sequence or of it changes an important functional domain of the protein 
or the protein conformation. A nonsense mutation causes a premature stop codon 
which can cause a truncated protein product to be produced, or more often, nonsense-
mediated mRNA decay. A silent mutation changes the nucleotide but does not change 
the amino acid. All of these different types of point mutations can also cause splicing 
errors when they occur in splicing donor or acceptor sites. Splicing errors may result in 
splicing of exons (exon skipping) or splicing at cryptic splice sites within introns or exons. 
Point mutations can also create novel donor or acceptor splice sites within exons or 
introns. 
1.2.2. Copy number variations (CNVs) 
Structural changes such as translocations and inversions are large changes that modify 
the structure of one or more chromosomes. These may be balanced, i.e. they do not 
change the copy number of the DNA segment. They may also be unbalanced, creating a 
copy number variation (CNV). It has been estimated that the mutation rate for de novo 
locus-specific CNVs is higher compared with nucleotide substitutions (Redon et al., 
2006). Most commonly there are two copies of a certain gene, one in each allele. Copy 
number gains of one additional copy are called duplications and copy number losses are 
called deletions. If they occur inside a gene, they may change the reading frame and a 
premature stop codon may arise. However, if a deletion or duplication causes an in-
frame mutation, it can produce a shorter or a longer gene product. Some CNVs can cover 
several megabases and can thus easily contain an entire gene or numerous genes (Zhang 
et al., 2009). 
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1.2.2.1. Mechanisms creating copy number variations 
Many different mechanisms can cause CNV formation. A summary of different 
mechanisms is presented in Table 1. Non-allelic homologous recombination (NAHR) is 
thought to be one of the most common mechanisms. NAHR is caused by misalignment 
and cross-over of non-allelic homologous DNA segments. These homologous DNA 
segments can be repetitive sequences such as segmental duplications (SD). NAHR 
requires so called minimal efficient processing segments such as SDs to take place. The 
homology of the SDs and the distance between the two segments affect the NAHR 
efficiency (Gu et al., 2008; Hastings et al., 2009; Sharp et al., 2006).  
Malfunction of the DNA repair mechanisms may also cause loss or gain of DNA 
segments. Non-homologous end joining (NHEJ) is a common mechanism to correct 
pathological double-stranded DNA breaks (DSBs). It is effective throughout the cell cycle 
and does not require a homologous chromosome or particular sequences to take place. 
NHEJ is flexible as the result of different nuclease, polymerase and ligase activities. NHEJ 
includes four steps: detection of the double-stranded break, molecular bridging of the 
broken DNA ends, modification of the ends, and ligation (Gu et al., 2008; Lieber, 2008).  
Microhomology-mediated end joining (MMEJ) is a rather recently suggested DNA-repair 
and CNV-formation mechanism. It is also called alternative NHEJ (alt-NHEJ).  
Microhomology, a small segment of DNA that is homologous between the joined DNA 
sites, is required for MMEJ. This microhomology is used to align the DNA sequences 
before joining the segments. NHEJ may also use microhomology (~1-4 nucleotides), but 
for MMEJ microhomology it is obligatory and the homologous stretch is usually larger 
(~5-25 nucleotides) (Lieber, 2008; McVey and Lee, 2008).  
Fork Stalling and Template Switching (FoSTeS) is a replication-based mechanism that 
causes CNVs. If the replication fork stalls during DNA replication, the lagging strand can 
disengage from the original template and anneal to another replication fork and then 
continue the DNA synthesis. If the strand switches to a fork located downstream 
(forward invasion), this causes a deletion. If it switches to an upstream-located fork 
(backward invasion), this causes a duplication (Lee et al., 2007).  
Microhomology-mediated break-induced replication (MMBIR) is another replication-
based repair mechanism. In MMBIR the 3’ overhang of the broken DNA strand invades 
another chromosome, such as the sister chromatid or the homologue, using 
microhomology, and continues the replication from there, up until the end of the 
chromosome (Bauters et al., 2008; Hastings et al., 2009; Vissers et al., 2009).  
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Table 1. Mechanisms creating copy number variations. This table summarises different CNV-
creating mechanisms and their characteristics. 
References: Gu et al., 2008; Kloosterman et al., 2011; McVey and Lee, 2008; Vissers et al., 2009, Liu et al., 2012. 
Chromosome shattering, also called chromothripsis, is a recently discovered 
phenomenon that is thought to be caused by one catastrophic event that results in 
complex rearrangements. Typically there is strong clustering of breakpoints. 
Chromothripsis is thought to be caused by many simultaneous double-stranded DNA 
breaks that are then repaired through non-homologous mechanisms (Kloosterman et 
al., 2011; Stephens et al., 2011). 
1.2.2.2. Repeat elements producing copy number variations 
Several repeat elements are known to be involved in creating CNVs. Alu repeats can be 
involved in homologous recombination, via two suggested ways. First, they may serve 
as binding sites for proteins necessary for homologous recombination. Second, they can 
promote DNA strand exchange directly themselves (Kolomietz et al., 2002). Different 
studies have suggested that Alu repeats could also mediate chromosomal 
rearrangements via non-homologous mechanisms such as NHEJ, FosTeS, or MMBIR 
(Shaw and Lupski, 2005; Vissers et al., 2009). Repetitive sequences such as Alu repeats 
Non-allelic 
homologous 
recombination 
NAHR Non-allelic homologous DNA 
segments misalign and 
crossing over occurs
Meiosis and 
mitosis
Homologous 
non-allelic 
sequence 
deletion, duplication, 
inversion, and mosaic 
rearrangements
Non-
homologous 
end joining 
NHEJ Detects a double-stranded 
DNA break, builds a 
molecular bridge, modifies 
the ends, and ligates
Meiosis and 
mitosis
Any sequence, 
microhomology 
can be used           
(1-4 bp), may 
leave an 
information scar
deletion, duplication, 
translocation
Microhomology-
mediated end 
joining 
(=alternative 
NHEJ)
MMEJ                 
(=alt-NHEJ)
The broken DNA is joined 
using microhomology
Mitosis Microhomology 
required             
(5-25 bp), may 
leave an 
information scar
deletion, 
translocation 
Fork Stalling and 
Template 
Switching 
FoSTeS The replication fork stalls, 
the lagging strand 
disengages from the 
template and anneals to 
another replication fork
DNA-
replication
Microhomology deletion, duplication, 
triplication, inversion, 
complex 
rearrangement
Microhomology-
mediated break-
induced 
replication 
MMBIR 3’ overhang of a broken DNA 
strand invades sister 
chromatid or the homologue 
and continues replication
DNA-
replication
Microhomology 
required, may 
leave an 
information scar
duplication, deletion, 
inversion, 
translocation, 
triplication, and loss 
of heterozygosity
Chromothripsis - One catastrophic event of 
simultanous DNA breaks is 
repaired
DNA repair Repair of up to 
hundreds of 
breakpoints
complex 
rearrangements
ResultAbbreviationName Mechanism Functions in Special features
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may predispose the rearrangement to additional deletions at the breakpoints 
(Kolomietz et al., 2002). Furthermore, it has been suggested that certain Alu elements 
play an important role in the constitutional as well as evolutionary chromosomal 
rearrangements (Shaw and Lupski, 2005). The DMD gene encoding dystrophin has been 
shown to carry different CNV deletions with scattered breakpoints that include Alu and 
tandem repeats (Nobile et al., 2002). In another study of congenital aberrations, it was 
shown that a repetitive element was identified in 70% of the studied breakpoints 
(42/60). These included different SINEs (such as different Alu repeats), LINEs, DNA 
repeats and long terminal repeats (Vissers et al., 2009). Altogether, there is a broad 
spectrum of different variations and mechanisms caused by repetitive elements of the 
genome. 
1.2.2.3. Copy number variations and disease 
Copy number variations may be benign or cause harmful effects, especially when 
including genes. CNVs are common in congenital as well as in acquired disorders. For 
example, when a CNV contains genes that are dosage-sensitive, or a deletion occurs in 
a region including haploinsufficient or imprinted genes, they are more likely to affect 
the phenotype. Even very small CNVs can cause problems if they disrupt a gene. 
Furthermore, CNVs may be pathogenic even if they do not specifically contain annotated 
disease-causing genes, but instead they may carry, for example, their transcription 
factors. 
Various microarray techniques have revealed a great number of novel CNVs during the 
last decade, however, many disease-related CNVs are likely yet to be discovered. 
Understanding the pathogenetic mechanism of a disorder is always important in every 
disease, whether it concerns a congenital disorder or an acquired disease such as cancer. 
The different CNV-inducing mechanisms (Table 1) work in different settings and can thus 
give an indication of the stage where the pathogenic rearrangement occurred.  
As mentioned above, many genomic disorders and syndromes are known to be caused 
by NAHR-induced CNVs. NAHR can occur in meiotic recombination and create either 
inherited or sporadic disorders. A well-known inherited CNV example is the 
chromosomal region 17p12 in which a deletion causes hereditary neuropathy with 
liability to pressure palsies (HNPP) and duplication of the same region causes Charcot-
Marie-Tooth disease type 1 (CMT1A). NAHR can also cause sporadic disorders due to 
recurrent de novo rearrangements. A deletion in the chromosomal region 17p11.2 
causes Smith-Magenis syndrome and a duplication Potocki-Lupski syndrome. This region 
of chromosome 17p is remarkably rich in LCR segments that predispose these particular 
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regions for NAHR. NAHR is also known to occur in mitotic cells, causing mosaic 
rearrangements which are especially common in cancer. The same pair of LCRs may 
utilize both meiotic and mitotic events, but not necessarily with the same frequency (Gu 
et al., 2008).  
NHEJ is effective throughout the cell cycle and tolerates some nucleotide loss or addition 
in the breakpoint. This explains the breakpoint heterogeneity as well as the so-called 
information scars that are often left in the repaired sites. Furthermore, these CNVs occur 
more randomly throughout the genome and are thus usually non-recurrent. NHEJ is also 
used to repair the physiologic DSBs that occur during the somatic recombination of the 
antigen receptors of the lymphocytes. The flexibility and imprecision of NHEJ further 
enhances antigen receptor diversity and the adaptive immune system. Moreover, 
inherited defects in this mechanism can cause severe combined immune deficiency 
syndrome (SCID) (Gu et al., 2008; Lieber, 2008). MMEJ (or alt-NHEJ) requires 
microhomology for alignment of broken ends and can thus only cause deletions in the 
breakpoint region. Both NHEJ and MMEJ are known to create translocations and 
rearrangements that are common in cancer cells (Bennardo et al., 2008; Gu et al., 2008; 
McVey and Lee, 2008).  
From the replication-based mechanisms, FoSTeS is also thought to use microhomology, 
however, it can cause duplications as well as deletions. Because the replication fork can 
switch the template several times, FoSTeS is also thought to be capable of causing large 
complex rearrangements (Gu et al., 2008; Liu et al., 2012). Furthermore, MMBIR can 
cause many types of rearrangements, including duplications, deletions, inversions, 
translocations, triplications, and loss of heterozygosity, and thus also imprinting 
disorders. MMBIR is thought to form non-recurrent CNVs, and it has been suggested to 
contribute to chromosomal instability, such as somatic changes in cancer cells and 
tumour formation (Hastings et al., 2009; Vissers et al., 2009).  
Chromothripsis was first described in cancer (Stephens et al., 2011), and shortly 
afterwards in constitutional diseases (Kloosterman et al., 2011). In constitutional cases, 
more than one chromosome is usually involved and the number of breakpoints is less 
than 25. In cancer, chromothripsis involves one or multiple chromosomes and there can 
be dozens or even hundreds of breakpoints (Kloosterman and Cuppen, 2013). 
1.2.2.4. Breakpoint analysis of copy number variations 
The different CNV mechanisms are effective in different environments (Table 1). For 
example, homology-dependent NAHR and homology-independent NHEJ are effective 
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during meiosis and mitosis, MMEJ acts in mitosis and FoSTeS and MMBIR during 
replication. Consideration must be taken, when studying the CNV breakpoint, regarding 
the fact that NAHR and NHEJ usually correct double-stranded breaks, whereas 
replication-based mechanisms correct single-stranded breaks. Furthermore, several 
mechanisms can use microhomology, such as MMEJ, MMBIR, FoSTeS, and NHEJ. The 
molecular fingerprint can indicate the replication mechanism. A molecular scar of 
inserted nucleotides at the breakpoint may indicate NHEJ, but also for example MMBIR. 
Many mechanisms may cause deletions and duplications, but MMEJ can only cause 
deletions, and MMBIR is versatile also causing inversions, translocations, triplications, 
and loss of heterozygosity. On the other hand, FoSTeS and chromothripsis may also 
cause complex rearrangements (Conrad et al., 2010; Vissers et al., 2009).  
The only way to elucidate the origin of the rearrangement is to reveal the exact 
breakpoints of the CNV. This may often be more difficult than anticipated. PCR-based 
sequencing has been used in previous studies but it can be extremely laborious. It also 
requires previous knowledge or estimation of the structure of the rearrangement, such 
as the orientation of the duplicated segment. This is why genome-wide shotgun 
sequencing has become popular in resolving the exact breakpoints of the CNVs. 
However, this is a rather expensive method to be used to further delineate already 
identified CNVs, especially in a large sample cohort. All in all, no method is perfect alone. 
For example, high copy number repeats and heterochromatin regions are extremely 
difficult to catch and verify with sequencing (Conrad et al., 2010). Unique parts of 
sequences are required to align the different pieces of sequence properly and this may 
not be achieved when dealing with long repetitive sequences.  
Even when the exact breakpoint has been identified, defining the causative method 
behind the CNV or rearrangement may be difficult. This is due to the fact that many 
mutational mechanisms can create similar breakpoint signatures. For example, 
microhomology can be found at breakpoints created by MMEJ, MMBIR, NHEJ, and 
FoSTeS (Conrad et al., 2010; Vissers et al., 2009). This demonstrates the current 
challenge when interpreting the CNV breakpoints and their origin. Nevertheless, this 
field of research has expanded in recent years and novel data will undoubtedly shed new 
light on how to best unravel these mechanisms in the future. 
1.3. Variant detection 
The identification of disease-causing variant(s) in each affected family is often important 
in the case of monogenic disorders. For many diseases, the identification of the 
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pathogenic variant(s) is needed to confirm the diagnosis. It is also essential for genetic 
counselling as it helps to determine the mode of inheritance and thus the recurrence 
risk in each family. Identifying novel disease-causing variants may further help to 
establish possible genotype-phenotype correlations of the disease. Characterizing new 
mutations may also help to elucidate the gene functions and to understand the 
pathogenetic mechanisms of the disease. Understanding the pathogenesis is a 
prerequisite for the development of specific therapies.  
Different variant detection methods are usually optimal for finding only certain types of 
variants. Heterogeneous diseases like nemaline myopathy (NM) that have several 
causative genes, some of them also lacking proper mutational hotspots, can make 
variant analysis very cumbersome. Even though the DNA samples from families with this 
muscle disorder have been extensively studied, many families remain where one or both 
pathogenic variants are yet to be identified. In some cases the suspected diagnosis might 
be incorrect. This may prohibit the identification of the disease-causing variants, if the 
appropriate genes are not tested. Even if the appropriate genes are tested, the variant 
detection methods may be limited in finding all types of mutations. Furthermore, it is 
also likely that there are novel genes yet to be identified. This accentuates the 
importance of developing novel variant detection methods. 
1.3.1.  Variant screening methods and Sanger sequencing 
Variants can be sought by direct gene sequencing from PCR products, but for large 
genes, such as NEB including 183 exons, a screening method preceding sequencing can 
be useful. The SSCP (single-stranded conformation polymorphism) or dHPLC (denaturing 
high-performance liquid chromatography) methods have previously been used to pre-
screen the genes (Jones et al., 1999; Orita et al., 1989; Sheffield et al., 1993; Underhill 
et al., 1996). These screening methods can help to point out the region in a large gene 
where a DNA change might be located and that needs to be sequenced further. This has 
been efficient in identifying small, heterozygous variants, but additional methods are 
needed since both or the second disease-causing variant of many patients remain 
unidentified after analysis by dHPLC followed by sequencing. Nowadays sequencing 
techniques have become much more powerful, and such screening methods are seldom 
used anymore. In addition to next generation sequencing, other methods have been 
developed that allow the examination of the entire human genome even in a single 
experiment.  
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1.3.2. Microarray 
The microarray method became available in the late nineties when comparative 
genomic hybridization (CGH), which was used for fixed metaphase chromosomes 
(Kallioniemi et al., 1993), was developed into probe-based arrays (Pinkel et al., 1998; 
Solinas-Toldo et al., 1997). This method allows determination of the copy number 
variation between the sample and a reference genome.  
Nowadays microarray-based methods are very commonly used and there are many 
different variations and applications. Gene expression microarrays from cDNA allow 
comparisons of different gene expression patterns between individuals or different 
tissues. Microarrays can also be used for micro-RNA profiling and studying protein 
interactions or epigenetic modifications. However, one of the most commonly used 
microarray applications is still the DNA-based aCGH (array comparative genomic 
hybridization), which detects copy number variations of different sizes in the genome. 
It can be based for example on SNP or CNV probes. A two-colour aCGH method is 
described in Figure 1. It is based on attaching thousands of probes to a surface, such as  
Figure 1. A schematic overview of the array-CGH method used in this study. 1) The same quantity 
(1000 ng) of patient DNA and reference DNA are digested and labelled with different fluorescent dyes. 2) 
The differently labelled DNAs are hybridized together on a glass slide. 3) The microarray slide is washed 
and the fluorescent intensities are scanned with a laser scanner. 4) The intensity values are transformed 
into a text format using the Feature Extraction Software (Agilent Technologies) and transformed and 
analysed in a graphic format using the CytoSure Interpret Software (Oxford Gene Technology). 
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a glass slide. The sample and reference DNA are labelled with different fluorescent dyes 
and they are hybridized together on the slide. The different fluorescent intensities are 
then measured and the copy numbers of each probe can be analysed. The resolution of 
the microarray depends on the number of probes and the targeting of the microarray.   
Chromosomal microarray (aCGH of the entire genome) is currently recommended as a 
first-tier diagnostic test for patients with unexplained intellectual disability, 
developmental delay, autism spectrum disorders, and multiple congenital anomalies. 
This is due to the much higher diagnostic yield (15-20%) compared with the conventional 
chromosomal karyotyping using G-banding (3%) (Miller et al., 2010).  
Microarrays are also commonly used in cancer research and diagnostics; they can help 
to identify cancer-specific variants or altered gene expression. This aids diagnosis, 
classifying, and estimating the prognosis of different malignancies (Shinawi and Cheung, 
2008). 
Microarrays can cover the whole genome or be more targeted, for example towards 
known syndromes. Furthermore, it has become possible to design targeted custom 
arrays to densely cover only the genes of interest. One example of a high-density custom 
array is the DMD-CGH array targeted for variant detection in the gigantic dystrophin 
gene where mutations cause dystrophinopathies (Bovolenta et al., 2008). In recent years 
various microarray methods have shown great success in identifying previously 
characterized as well as novel copy number variations. 
1.3.3. Multiplex Ligation-dependent Probe Amplification 
The multiplex ligation-dependent probe amplification (MLPA) method has successfully 
been used in variant detection and diagnostics of several genes. The MLPA method is 
based on multiplex PCR amplification of selected DNA regions of different lengths. The 
products are then separated by fragment analysis and the copy number of each 
fragment can be analysed compared to the reference DNA (Schouten et al., 2002; 
Schwartz and Duno, 2004; Sulek et al., 2011). Even though the MLPA technique allows, 
in an optimal situation, for detecting of the copy numbers of tens of different genomic 
regions, there are commercially available kits only for a selection of genes. However, 
self-designed synthetic MLPA sets can be designed for almost any region of interest 
(Stern et al., 2004). 
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1.3.4. Next Generation Sequencing 
Next generation sequencing (NGS) techniques have revolutionized sequencing 
possibilities. While the costs of sequencing have decreased, throughput has increased. 
NGS includes exome sequencing, whole-genome sequencing, and targeted sequencing 
approaches. There are different NGS sequencing techniques, however, they follow the 
same principle. The first step is template preparation. A DNA library is created by 
fragmenting genomic DNA and amplifying it. Using synthetic oligonucleotides, the 
fragments can be attached to a sequencing media (such as a flow cell, slides, beads etc.) 
and amplified creating a fragment or a mate-paired DNA library. Sequencing of the 
fragments can be accomplished using many different approaches. Sequencing can be 
based on differentially labelled nucleotides, change in voltage or release of photons 
after adding nucleotides in predefined order, or other methods that allow identifying 
the added nucleotides to create the sequence. After sequencing, the reads are aligned 
to a known reference sequence or assembled to create a consensus sequence for variant 
analysis (Desai and Jere, 2012; Metzker, 2010; Ng et al., 2009).  
For example, in the Agilent Sure Select approach the DNA library is created by 
fragmenting the DNA and ligating adapters to both ends of each fragment. At this stage, 
the library can be hybridized with a selected capture kit to select the regions, genes or 
exons of interest. For example when using the Illumina sequencing platform (MiSeq or 
HiSewq), the fragments are then attached to a flow cell coated with primers. Solid-phase 
bridge PCR amplification is done creating millions of clusters on the flow cell. The 
sequencing is done using four differently labelled nucleotides (A, T, G, C) that emit 
different fluorescence after laser excitation that can be identified to create the 
sequence. The error rate of MiSeq nucleotide substitutions has been reported to be 
~1%, which is similar to Sanger sequencing with the Genome Analyzer (Desai and Jere, 
2012; May et al., 2015). 
The newest forms of sequencing technology are the single-molecule sequencing 
techniques that do not require PCR amplification. This provides the next step of 
sequencing technology that is unrestricted by the limitations of PCR. It allows the 
generation of long stretches of DNA and sequencing also of such types of DNA regions 
that are difficult to amplify. This could possibly reduce sample handling time as well as 
required quantities of DNA and avoid errors produced by the amplification (Xuan et al., 
2013). Sequencing through nanopores is a currently emerging technique that has also 
been called fourth-generation sequencing. The MinION platform by Oxford Nanopore 
Technologies is the first nanopore sequencer to have been commercialized, although, 
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still being further developed by the users. The MinION technique is based on directly 
measuring the changes in electrical current as one individual strand of DNA sequence 
passes through one of the 500 pores on the nanopore platform. In theory, this allows 
the analysis of DNA stretches of unlimited size. The current limitations of these methods 
include requirement of high-quality DNA, low sequencing capacity, and high error rate 
up to ~10-30% (personal experience). Currently, read lengths of ~40 kb have been 
reported which are a great deal longer than traditional sequencing can provide. Using 
this approach, the copy number for a cancer-testis gene family (CT47) in human 
chromosomal region Xq24 was sequenced even though it had been inaccessible due to 
the high repetitiveness thus far. This, in particular, shows the potential of the fourth-
generation sequencing techniques that do not require PCR (Jain et al., 2015; Loman and 
Watson, 2015). 
All in all, NGS techniques have made sequencing exponentially more efficient. They are 
also optimal methods for hunting novel disease-causing genes and variants, because 
they do not require previous knowledge of the genes. However, when trying to identify 
novel pathogenic genes, it is highly beneficial if family trios, including parents and 
affected child, or even larger family sample sets are available for testing. Including 
several samples makes it possible to exclude the majority of the discovered benign 
variants when comparing the sample from the Index Patient to samples from the non-
affected members of the family.  
Whole-exome sequencing (WES) is currently widely used in research and is steadily 
making its way into diagnostics as well. This method allows sequencing at the level of an 
entire exome at once (Ng et al., 2009). However, the choice of exome capture or 
enrichment kit defines which genes and exons are included in the study. Five commonly 
used patforms, Illumina Nextera Rapid Capture Exome, Illumina TruSeq Exome, Agilent 
SureSelect XT Human All Exon, Agilent SureSelect QXT, and NimbleGen SeqCap EZ 
Human Exome Library, all use DNA or RNA baits for targeting. However, they differ in 
genomic fragmentation method, target region selection, bait length and density, as well 
as the molecules used for capture. This causes differences in their gene and exon 
coverage. Different platforms currently target 40-60 Mb of the human genome 
(Chilamakuri et al., 2014; Shigemizu et al., 2015). In a recent study, Agilent SureSelect 
XT Human All Exon platform achieved the highest sequence coverage in the coding 
region, the Illumina platform showed the highest performance in detecting medically 
interesting variants, whereas Nimblegen was superior in detecting variations in the 
untranslated regions (Shigemizu et al., 2015).  
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Whole-genome sequencing includes, at least in theory, the entire genome, yet it is a lot 
more expensive and it produces a lot more data. However, there are genomic regions 
such as highly repetitive segments of DNA that cannot be covered because they lack 
unique sequence, which would be required to align and locate the sequences. In 
addition, NGS can also be done on targeted genomic region(s) of interest. The NGS 
approach can thus be chosen based on the study expectation, number of genes of 
interest, the total size of the regions, whether exonic data is adequate or whether 
intronic regions are also needed etc. The targeted sequencing approach provides the 
most cost-effective way of covering the genes of interest in high read depth. This 
approach is used for example for genetic diagnostics of the Usher syndrome. In this 
disorder, 12 causative genes have been identified that cover 80% of the disease-causing 
variants (Jamuar and Tan, 2015; Krawitz et al., 2014). There are even commercially 
available panels targeting, for example, cancer genes and assisting in oncology decision 
making (Weiss et al., 2015). However, a study comparing WGS, WES and targeted 
sequencing suggested that WES currently remains the preferred choice when searching 
for the genetic cause of intellectual disabilities, where many of the disease-causing 
variants remain yet to be identified (Sun et al., 2015). WGS currently offers only limited 
advantages over WES and when cost-efficiency and turnaround time are taken into 
consideration, WES and targeted panels outperform WGS in a clinical setting (Sun et al., 
2015). 
In any next generation sequencing approach, the analysis of the large amounts of 
generated data is currently the most challenging part of the process. This is also a major 
reason why the NGS technique has been implemented to the clinical setting slowly and 
with caution. In clinical work it is important that the samples can be analysed promptly 
and interpreted easily and with great certainty and reliability (Desai and Jere, 2012).  So-
called unsolicited or incidental findings create a great challenge, and the first 
recommendations on how to handle these findings have been published. For example, 
the American College of Medical Genetics and Genomics (ACMG) has listed genes in 
which pathogenic variants are known to cause medically actionable disorders, and thus 
should be reported, unless the individual chooses to opt out of such analysis (ACMG 
Board of Directors, 2015; Green et al., 2013). On the other hand, the European Society 
of Human Genetics (ESHG) recommends a much more cautious approach in reporting 
unsolicited findings and favours targeted approaches over WES and WGS only when 
necessary (van El et al., 2013). Currently, the practice seems to differ between different 
laboratories. Nevertheless, it is highly important that each institution reaches a 
consensus regarding the ethical issues when implementing NGS into clinics. 
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1.4. Assessing variant pathogenicity 
It is not always easy to interpret the effect that a variant may cause at the functional 
level. The variant itself combined with the location and its surroundings are important 
in this estimation. Variants including genes or residing inside genes, in their exons and 
conserved DNA sequences are more likely to cause a pathogenic effect. Variants outside 
genes or inside the gene introns, excluding splice sites, are less likely to cause an effect. 
This is why every identified DNA change needs to be evaluated carefully to determine 
whether they are benign polymorphisms or disease-causing variants.  
A number of databases can be used to interpret the potential pathogenicity of the 
variants, such as Leiden Open Variation Database (LOVD), Exome Variant Server (EVS), 
or Exome Aggregation Consortium (ExAC) Browser. The consequences that the change 
creates at the DNA level can be estimated using different softwares, such as Polyphen 
(Polymorphism Phenotyping), SIFT (Sorting Intolerant from Tolerant), MutationTaster, 
Mutation Assessor (MASS), FatHMM, Combined Annotation Dependent Depletion 
(CADD), and Condel (Consensus Deleteriousness score)  (Adzhubei et al., 2010; 
Gonzalez-Perez and Lopez-Bigas, 2011; Kircher et al., 2014; Ng and Henikoff, 2003; Reva 
et al., 2011; Schwarz et al., 2014; Shihab et al., 2013). The softwares estimate the variant 
pathogenicity by measuring sequence conservation, assessing the impact on protein 
structure and function, or quantifying the pathogenic potential using diverse genomic 
information (Grimm et al., 2015).  
The potential pathogenicity of copy number changes can also be estimated using various 
databases, such as Database of Genomic Variants (DGV), DECIPHER (DatabasE of 
genomiC varIation and Phenotype in Humans using Ensembl Resources), and ECARUCA 
(European Cytogeneticists Association Register of Unbalanced Chromosome 
Aberrations), presenting information about benign and pathogenic variations described 
previously. The changes can be further studied at the RNA, amino acid, and protein 
levels using functional studies. 
Despite using several databases for variant interpretation, variants of unknown 
significance (VUS) may remain and they can for example be categorized as likely benign 
or likely pathogenic (Jamuar and Tan, 2015). When more data has been collected, the 
significance of these variants may be resolved in the future. Guidelines have been 
published on how to write the reports and which variants should be reported 
(MacArthur et al., 2014).  
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2. Skeletal muscle 
There are three types of muscles in the human body; skeletal muscle, cardiac muscle 
and smooth muscle. Skeletal muscles are striated muscles that enable voluntary muscle 
movements. Cardiac muscle is also striated, but cardiac movements are non-voluntary 
and this type of muscle is found only in the heart. Smooth muscle is non-striated and its 
contractions are non-voluntary. Smooth muscles are found, for example, in the 
gastrointestinal tract and the walls of blood vessels. 
There are several hundred skeletal muscles in human and the number varies between 
different estimations. Proximal muscles are the ones close to the trunk and distal 
muscles are further away from the trunk. The muscles vary in shape and size, depending 
on their function in the body. One muscle fibre consists of a single cell that has emerged 
from fused adjacent cells and thus one fibre usually contains multiple nuclei. Several 
muscle fibres form fascicles which bundle to form the muscle (Stone and Stone, 2011). 
Figure 2A shows the structure of the striated muscle. 
2.1. Skeletal muscle fibre types 
Skeletal muscles consist of different muscle fibre types. Type 1, slow fibres and type 2A 
fast fibres use oxidative phosphorylation for generating ATP (adenosine triphosphate) 
which makes them optimal for endurance. Type 2B, ultrafast fibres use mainly glycolysis 
which makes them optimal for short-duration maximal performance. Most human 
muscles include a typical combination of Type 1 and 2 fibres, depending on the muscle. 
In myopathies the fibre size can vary abnormally (Spangenburg and Booth, 2003). The 
fibres can be hypotrophic (smaller than normal because of failure to grow normally), 
atrophic (smaller than normal because of degeneration) or hypertrophic (larger than 
normal). In human, usually both fibre types are present roughly in equal proportions, 
although there is some variability between different types of muscle. In a state called 
fibre type disproportion the distribution is not equal. This means that the diameter of 
the type 1 fibres are at least 25% smaller than that of the type 2 fibres. This is a common 
phenomenon in the congenital myopathies (Brooke and Engel, 1969; Clarke and North, 
2003; Jungbluth and Wallgren-Pettersson, 2013). 
2.2. The sarcomere 
One muscle fibre cell consists of a bundle of myofibrils enveloped by a cell membrane, 
the sarcolemma. Each myofibril is made up of adjacent sarcomeres. One sarcomere is 
approximately 2-3 µm long and 1-2 µm in diameter and it is the basic functional unit of 
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the muscle. The striated appearance of skeletal muscle is formed by the organised 
alignment of its different bands (Figure 2B). Z-discs separate one sarcomere from the 
adjacent one. The I-bands surrounding the Z-discs are formed by the thin actin filaments, 
and proteins such as tropomyosins and troponin complexes bound to it. Figure 2C shows 
how two nebulin molecules span each thin filament. The A-bands are formed by thick 
myosin filaments. The M-band connects the myosins to the titin filaments in the middle 
of the sarcomere. Actin and myosin are responsible for the transduction of chemical 
energy to mechanical force during muscle contraction (Craig and Padron, 2004; 
Dubowitz et al., 2013).  
Figure 2.  
A schematic 
picture of the 
muscle and the 
sarcomere. 
A) The muscle 
organization. 
B) An electron-
microscopic 
photograph of 
the sarcomere. 
C) A schematic 
picture of the 
sarcomere. 
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2.3. Muscle contraction 
Muscle contraction starts when a motor neuron action potential reaches the 
neuromuscular junction and releases Ca2+ from the sarcoplasmic reticulum into the 
muscle fibre. Troponin binds the released Ca2+, causing a change in the troponin-
tropomyosin complex. This exposes the myosin binding sites, allowing actin-myosin 
interaction. The myosin ATPase hydrolyses ATP resulting in a conformational change in 
the globular head of myosin. This allows myosin to move along the actin filament. 
Myosin heads are released from actin as the next ATP molecule binds to myosin. When 
this occurs simultaneously in several myofibrils, it shortens the muscle fibre I-bands and 
the muscle contracts. The muscle contraction is released when Ca2+ is withdrawn from 
the sarcoplasm (Dubowitz et al., 2013; Stone and Stone, 2011). 
2.4. Sarcomeric proteins 
Sarcomeres are very complex units containing numerous proteins and their subunits. 
The functions of some of the proteins that are also known to be involved in nemaline 
myopathy are presented here. The genes and their locations are marked according to 
the Genome Reference Consortium Human Build 37 (GRCh37/hg19). 
2.4.1. Actin 
Actin is one of the most abundant proteins in human cells. There are six types of actin 
proteins that are expressed differently in different cells. β- and γ-actins are expressed 
virtually in all cells, as they are part of the cytoskeleton of the cell. The α-skeletal, α-
cardiac, α-smooth muscle, and γ-enteric actin are tissue-specific. Skeletal α-actin has a 
central role in muscle contraction. Skeletal α-actin monomers polymerise forming a 
filamentous helical structure creating the backbone of the muscle thin (actin) filament 
of the sarcomere. Skeletal α-actin has several binding sites for other proteins, such as α-
actinin, nebulin, tropomyosin, and the troponin complex. This explains why the different 
isoforms of actin are very homologous, especially in terms of their binding sites. The 
skeletal muscle α-actin-encoding gene, ACTA1 is located in chromosomal region 1q42 
(GRCh37/hg19). ACTA1 is particularly conserved and rarely tolerates any mutations 
(Hanauer et al., 1983; Kabsch and Vandekerckhove, 1992; Laing et al., 2009; Nowak et 
al., 1999). Mutations can interfere with folding and polymerization, create aggregates, 
affect expression and cause changes in myosin force generation (Feng and Marston, 
2009).  
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2.4.2. Nebulin 
Nebulin is a gigantic structural protein (600-900 kDa) located mainly in the thin (actin) 
filaments of the sarcomeres in striated muscle. Two α-helical nebulin molecules span 
the entire thin filament (Pfuhl et al., 1996). Furthermore, nebulin determines the 
minimum length of the thin filament and regulates its contractility by actomyosin 
interactions and force generation (Bang et al., 2006; Chandra et al., 2009; Witt et al., 
2006). 
Nebulin is a highly repetitive protein; it periodically binds actin, calmodulin, tropomyosin 
and the troponin complex. Most of nebulin consists of 30-35 amino acid long simple 
repeats, each containing one actin-binding site. Nebulin binds 179-239 actin monomers 
of the thin filament, depending on the isoform. Moreover, simple repeats are arranged 
into 22-30 super repeats (Chandra et al., 2009; Labeit et al., 1991; Pfuhl et al., 1996; 
Wang, 1996). Every super repeat binds to the tropomyosin-troponin complex that forms 
a calcium-linked regulatory complex. The vast majority of nebulin is expressed in striated 
muscle, but it has also been detected at a low level in the heart and brain (Joo et al., 
2004; Kazmierski et al., 2003; Laitila et al., 2012). Nebulin is encoded by NEB located in 
the chromosomal region 2q23.3. Mutations in the nebulin gene have been shown to 
alter the affinity in nebulin-actin, as well as nebulin-tropomyosin interactions (Marttila 
et al., 2014). 
2.4.3. Tropomyosins 
The tropomyosins are a family of proteins that bind to actin filaments. Four different 
genes have been characterized encoding different tropomyosin proteins and isoforms. 
α-Tropomyosinfast is mainly expressed in the heart and in type 2 fast skeletal muscle 
fibres. It is encoded by the TPM1 gene that is located in chromosomal region 15q22.2. 
β-Tropomyosin is mainly expressed in skeletal muscle, mainly in slow, type 1 muscle 
fibres, but to a lesser extent also in type 2 fast fibres. It is encoded by TPM2 located in 
chromosomal region 9p13.3. α-Tropomyosinslow is expressed in slow, type 1 muscle 
fibres and it is encoded by TPM3 located in the chromosomal region 1q21.3. Muscle-
specific α- and β-tropomyosin are alpha-helical coiled-coil proteins that form dimers 
which bind head-to-tail along the thin actin filament. The TPM4 gene located in the 
chromosomal region 19p13.12 encodes tropomyosin expressed in tissues other than 
muscle. The separate isoforms have differences in their functional domains that bind for 
example actin, tropomodulin, and troponin. Tropomyosins act together with the 
troponin complex regulating the Ca2+-dependent actin-myosin interaction during muscle 
contraction. TPM1 and TPM3 have their own internal promoters for producing low 
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molecular weight tropomyosin isoforms also in other tissues (Gunning et al., 2005; Laing 
et al., 1995; Perry, 2001). Mutations in TPM2 and TPM3 have been identified all along 
the genes. The majority of the mutations have been shown to affect tropomyosin-actin 
interaction. Mutations causing increased Ca2+ sensitivity resulting in hypercontractile 
molecular phenotypes have also been described. In addition, a minority of the mutations 
have been shown to interfere with tropomyosin head-to-tail binding, affecting the 
polymerisation of tropomyosin (Marttila et al., 2014). 
2.4.4. The troponin complex 
The troponin complex is formed by three different troponin protein subunits. The 
various troponins have been named after their first function discovered. Troponin I 
inhibits the actin-myosin interaction, troponin T binds tropomyosin, and troponin C 
binds calcium, in addition to their other interactions and functions. There are several 
genes encoding troponins. Their different isoforms are usually specific for a certain 
skeletal muscle fibre type or for cardiac muscle (Tiso et al., 1997). The only troponin 
currently associated with nemaline myopathy is troponin T encoded by the TNNT1 gene 
in the chromosomal region 19q13.42 (Johnston et al., 2000). A recessive truncating 
mutation found in the Old Order Amish population in TNNT1 causes lower affinity of 
troponin T for tropomyosin and thus inefficient incorporation of the troponin complex 
into the thin filament (Wang et al., 2005). 
2.4.5. Cofilin 
Cofilins belong to a family of proteins that are known to regulate actin filament 
dynamics. Cofilin 2 is expressed in skeletal muscle and it controls actin polymerization 
and depolymerization in a reversible manner. Cofilin 2 is encoded by CFL2 located in the 
chromosomal region 14q13.1 (Thirion et al., 2001). It has been suggested that mutations 
in CFL2 may exert their effects by decreasing regenerative repair and increasing 
apoptosis and mitochondrial dysfunction in skeletal muscle (Morton et al., 2015). 
2.4.6. Kelch repeat-containing proteins 
Kelch repeat-containing proteins belong to a family of proteins that contain a BTB 
domain as well as several Kelch repeats. The Kelch repeat forms a so called beta-
propeller found in several different proteins allowing protein-protein interaction. The 
BTB domain helps protein interactions and is found, for example, in some Kelch proteins 
and/or proteins that bind actin or nuclear DNA (Adams et al., 2000; Albagli et al., 1995). 
These proteins have been discovered to have many different functions such as being 
transcription factors and participating in cytoskeleton regulation. Recently three of 
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these proteins have been found to carry pathogenic variants that cause nemaline 
myopathy. Kelch repeat and BTB domain-containing protein 13 was the first to be 
associated with NM. The encoding KBTBD13 gene is located in the chromosomal region 
15q22.31 (Sambuughin et al., 2010). Recently, two other Kelch-like proteins have been 
associated with NM: Kelch-like protein 40 and 41, encoded by KLHL40 (=KBTBD5) in the 
chromosomal region 3p22.1 (Ravenscroft et al., 2013) and KLHL41 (=KBTBD10) in the 
chromosomal region 2q31.1 (Gupta et al., 2013), respectively. Recently, it was shown 
that KLHL40 promotes NEB and LMOD3 stability, and the abundance of these proteins 
was reduced in the skeletal muscles of Klhl40-/- mice (Garg et al., 2014). KLHL40 has also 
recently been shown to be essential for muscle myogenesis and all three proteins have 
been shown to be connected to the ubiquitin proteasome pathway. This may be a link 
to NM pathogenesis (Gong et al., 2015; Sambuughin et al., 2012).  
2.4.7. Leiomodin-3 
Leiomodins form a subfamily within the group of tropomodulins. LMOD1 is found in 
smooth muscle and LMOD2 in cardiac muscle (Conley et al., 2001). Leiomodin-3 
(LMOD3) is expressed in striated muscle and it localizes to the pointed end of the 
sarcomeric thin filaments. It includes predicted tropomyosin- and actin-binding sites and 
is predicted to contribute into stabilizing the thin filament. Recently, mutations in 
LMOD3 have been identified in in patients with severe NM (Yuen et al., 2014). LMOD 
was recently shown to localize to the A band of the sarcomere and to be essential in 
sarcomere assembly, embryonic myofibrillogenesis, and sarcomere integrity (Garg et al., 
2014; Nworu et al., 2015; Tian et al., 2015).  
 
3. Nemaline myopathy and related disorders 
3.1. Nemaline myopathy 
Nemaline (rod) myopathy (NM) (MIM IDs from the database of Online Mendelian 
Inheritance in Man: NEM1 #609284, NEM2 #256030, NEM3 #161800, NEM4 #609285, 
NEM5 #605355, NEM6 #609273, NEM7 #610687, NEM8 #615348, NEM9 #615731, 
NEM10 #616165) is one of the most common congenital myopathies. Two groups 
described NM as a novel disease entity in 1963 (Conen et al., 1963; Shy et al., 1963). The 
typical histological findings include the presence of nemaline bodies (rods) in the muscle 
fibres. Nemaline bodies are aggregates of Z-disc and thin-filament proteins of the muscle 
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sarcomere (Conen et al., 1963; Schroder et al., 2003; Shy et al., 1963; Wallgren-
Pettersson et al., 1995). 
The severity of the disease varies widely and thus NM can be described as a 
heterogeneous group of muscle disorders. NM is typically characterized initially by 
proximal muscle weakness (Figure 3), however, the phenotypes vary from neonatally 
lethal forms to mild muscle weakness. Four different NM patients presenting typical or 
severe NM are shown in Figure 2. They have mutation either in the NEB or ACTA1 gene. 
Because of the clinical heterogeneity, NM has been divided into six clinical subgroups; 
typical, intermediate and severe congenital NMs, the mild childhood/juvenile onset, the 
adult-onset form and the so-called other forms of NM (Wallgren-Pettersson et al., 1999; 
Wallgren-Pettersson and Laing, 2000). Table 2 presents these different NM subgroups 
and their clinical criteria in more detail. Pathogenic variants in ten different genes have 
been published as causing NM. The disease can be inherited as an autosomal recessive 
(AR) or autosomal dominant (AD) trait, or it can be due to a de novo dominant mutation 
(Jungbluth and Wallgren-Pettersson, 2013).  
 
Table 2. NM phenotype categories. This table summarises the clinical criteria for different forms 
of NM (modified from Wallgren-Pettersson et al., 2004).  
Form of NM Clinical inclusion criteria 
Severe 
Onset at or before birth; no spontaneous movements; no spontaneous 
respiration, or with severe contractures or fractures at birth 
Intermediate 
Infantile onset; patient breathing and moving at birth, but unable to 
maintain respiratory independence, or to sit and walk independently; use 
of wheelchair before the age of 11 years; contractures developing in early 
childhood 
Typical 
Infantile onset; typical distribution of muscle weakness (weakness most 
pronounced in facial, bulbar, and respiratory muscles, neck flexors and 
limb-girdle muscles; initially proximal, later also distal involvement); 
motor milestones delayed but reached; course slowly progressive or non-
progressive 
Mild childhood or 
juvenile onset 
Childhood or juvenile onset 
Adult onset Adult onset 
Other forms of 
NM 
Unusual associated features such as cardiomyopathy, ophthalmoplegia, 
or unusual distribution of muscle weakness 
Distal myopathy  Mainly distal involvement 
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3.2. The nebulin gene (NEB) 
The main cause of recessively inherited NM are mutations of the nebulin gene (NEB, 
MIM *161650). NEB consists of 183 exons spanning 249 kb of genomic sequence, 
making it one of the largest genes in the human genome. There is only one initiation 
and termination codon in NEB, but several alternatively spliced exons theoretically give 
rise to hundreds of different nebulin isoforms (Donner et al., 2004; Pelin and Wallgren-
Pettersson, 2008). It has been hypothesized that the large variety of different nebulin 
isoforms is needed because of the diverse requirements on muscle tissue at different 
stages of development, in different muscles and fibre types (Kazmierski et al., 2003; 
Labeit et al., 2011; Laitila et al., 2012). Alternatively spliced exons include  
 
Figure 3. Nemaline 
myopathy patients 
with typical and 
severe NM caused 
by two recessive 
NEB mutations or 
one dominant 
ACTA1 mutation 
(Wallgren-
Pettersson, 1989; 
Wallgren-
Pettersson, 1990; 
Wallgren-
Pettersson et al., 
2004). 
The pictures are 
reprinted and modified 
with the permission of 
their copyright 
owners: Wallgren-
Pettersson et al, 1989, 
Journal of the 
Neurological Sciences, 
89,1-14, Elsevier Limited 
and Wallgren-Pettersson 
et al, 2004, 
Neuromuscular 
Disorders, 14, 461-470, 
Elsevier Limited. 
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exons 63-66, 143-144, and 167-177. Exons 63-66 form a cluster of exons which is either 
present in or absent from the transcript. The expression of the exon pair 143 and 144 is 
mutually exclusive, while exons 167-177 are independently spliced. In addition, there is 
a triplicate region (TRI), a block of eight exons that is repeated three times (82-89, 90-
97, 98-105) in the middle of the gene. This region is also thought to undergo alternative 
splicing (Donner et al., 2004; Pelin and Wallgren-Pettersson, 2008). The region is difficult 
to study due to its repetitiveness and high homology. Overall, variant analysis of NEB is 
demanding due to the large size and complexity of the gene. Furthermore, the 
mutations are spread all along the large gene, which contributes to making variant 
analysis very laborious.  
 
3.3. Other nemaline myopathy-causing genes 
Many of the sporadic NM cases are caused by de novo mutations of the ACTA1 
(MIM *102610) gene. These most commonly cause the severe form of NM. Also familial 
AD, AR, and somatic mosaic mutations have been identified. Mutations are spread all 
along the six coding exons (Laing et al., 2009; Nowak et al., 1999). In TPM2 
(MIM *190990) and TPM3 (MIM *191030), AD mutations are most common, usually 
causing mild or typical NM (Donner et al., 2002; Laing et al., 1995; Marttila et al., 2014; 
Tajsharghi et al., 2007). AR mutations in TPM3 have also been identified causing severe 
forms of NM (Donner et al., 2002; Lehtokari et al., 2008; Marttila et al., 2014). In TNNT1 
(MIM *191041), a recessive nonsense mutation has been identified in the Old Order 
Amish population causing severe NM when present in a homozygous form (Johnston et 
al., 2000). Furthermore, two NM families outside the Amish population have been 
characterized with pathogenic variants in TNNT1. A Hispanic patient was identified with 
another homozygous nonsense mutation, as well as a Dutch pedigree in which the 
affected members carried either compound heterozygous or homozygous variants in 
TNNT1 (Marra et al., 2015; van der Pol et al., 2014). In CFL2 (MIM *601443), two 
different homozygous missense mutations have been identified, one in a sibling pair 
affected by NM, and another in a sibling pair with a congenital myopathy with features 
of NM and myofibrillar myopathy (Agrawal et al., 2007; Ockeloen et al., 2012). In 
addition, a homozygous frameshift mutation has been identified in a patient with severe 
NM (Ong et al., 2014). The most recent NM genes identified encode Kelch-family and 
Kelch-like-family proteins. In KBTBD13 (MIM *613727), three different dominant 
mutations were characterized in four NM families (Sambuughin et al., 2010). In KLHL40 
(=KBTBD5, MIM *615340), 19 different AR mutations were identified in 28 probands 
with a very severe form of NM characterized by fetal akinesia (Ravenscroft et al., 2013).  
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Table 3. Nemaline myopathy genes and modes of inheritance (modified from Jungbluth and 
Wallgren-Pettersson, 2013). 
Chromosomal regions are marked according to GRCh37. Abbreviations: AD=autosomal dominant, AR=autosomal 
recessive, NM=nemaline myopathy. 
Five patients were identified with homozygous or compound heterozygous mutations in 
KLHL41 (=KBTBD10, MIM *607701), with truncating mutations causing severe and 
missense mutations a milder form of NM (Gupta et al., 2013). Recently, the tenth 
causative NM gene, LMOD3 (MIM *616112) was identified; 21 patients in 14 families 
were shown to have homozygous or compound heterozygous mutations in this gene, 
causing the severe form of NM (Yuen et al., 2014). Table 3 summarises all the known 
genes and their modes of inheritance in causing NM. 
3.4. Nemaline myopathy-related disorders 
Pathogenic variants in NEB can also cause other disorders besides nemaline myopathy. 
These include core-rod myopathy and various distal myopathies with or without 
nemaline bodies. 
Distal nebulin myopathy has been diagnosed in patients in four Finnish families who 
presented only distal weakness, and no nemaline bodies could be detected in the 
routine histological examination. The identified pathogenic NEB variants in these 
families are also known to cause NM when they appear in compound heterozygous form 
with more disruptive NEB mutations (Wallgren-Pettersson et al., 2007).  
Distal nemaline myopathy has been diagnosed in two families with NEB mutations, 
presenting distal weakness and showing nemaline bodies (Lehtokari et al., 2011). 
ACTA1 1q42.13 Actin, α-skeletal de novo/ 
AD/AR
severe most common, also intermediate, 
typical, mild and unusal ("other") forms
MIM *102610
NEB 2q23.3 Nebulin AR typical most common, all other forms also MIM *161650
TPM3 1q21.3 Tropomyosin,  α-slow AD/AR AD variable,  AR usually severe MIM *191030
TNNT1 19q13.42 Troponin T, slow AR severe ("Amish type", with tremors) MIM *191041
TPM2 9p13.3 Tropomyosin, β AD variable MIM *190990
CFL2 14q13.1 Cofilin 2 AR unusual ("other" ) form (severity as in typical 
form, unusual distribution of muscle 
weakness)
MIM *601443
KBTBD13 15q22.31 Kelch repeat and BTB 
domain-containing 
protein 13
AD childhood onset MIM *613727
KLHL40 3p22.1 Kelch-like protein 40 AR severe MIM *615340
KLHL41 2q31.1 Kelch-like protein 41 AR severe and milder MIM *607701
LMOD3 3p14.1 Leiomodin-3 AR severe MIM *616112
OMIM numberForm of NM (phenotype)Gene
Chromosomal 
region Protein
Mode of 
Inheritance
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Core-rod myopathy is another disorder in which pathogenic NEB variants have been 
identified in one family. This disorder presents with severe generalized muscle weakness 
and the muscle biopsy showing cores in addition to nemaline bodies. Cores are a typical 
finding in another congenital myopathy, central core disease (Romero et al., 2009). 
Childhood-onset distal myopathy with rods and cores has been characterized in one 
patient. It is a novel disease entity caused by compound heterozygous mutations in NEB, 
the patients presenting with a distal distribution of limb muscle weakness, and showing 
nemaline rods and cores in the muscle biopsy (Scoto et al., 2013). 
Mutations in ACTA1, TPM2, TPM3, and CFL2 also underlie other myopathies. These 
include actin myopathy, congenital fibre type disproportion, central core disease, multi-
minicore myopathy, intranuclear rod myopathy, cap myopathy, NM-myofibrillar 
myopathy, distal myopathies, distal arthrogryposis, and Escobar syndrome (Jungbluth 
and Wallgren-Pettersson, 2013).  
This variety of mutations in different genes causing the same disorder, and mutations in 
the same gene causing different disorders, shows the remarkable clinical and genetic 
overlap of the congenital myopathies. In addition, there is currently no clear genotype-
phenotype correlations for example for the pathogenic NEB variants, and the severity of 
the disease can vary even within the same family. Therefore, histological studies are 
important in the diagnosis of these patients. There is still much to learn about these 
disorders, thus mutation detection and the discovery of new genes is a valuable pursuit. 
Functional studies are of course the following step after mutation identification, to 
reveal the pathogenetic mechanisms of these disorders. Only after that is the 
development of potential specific therapies possible.   
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AIMS OF THE STUDY 
This Doctoral Thesis is a part of a larger study of nemaline myopathy and related 
muscular disorders. It was aimed to design and implement novel variant detection 
methods for use in NM diagnostics and reveal novel disease-causing variants in the 
known NM genes, as well as to identify novel NM genes. 
 
The aims of this study were to: 
1. Design and validate a custom copy number microarray targeting the NM genes 
2. Identify novel pathogenic variants in NEB and the other known NM-causing 
genes 
3. Identify novel disease-causing NM gene(s) using whole-exome sequencing 
4. Contribute by variant identification to the search for genotype-phenotype 
correlations in NM patients with NEB mutations 
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MATERIALS AND METHODS 
4. Patient and control samples 
4.1. Patient samples 
This study has been approved by the Ethics Committee of the Children's Hospital, 
Helsinki University Central Hospital. The patients or their guardians have given their 
consent for their samples and data to be included in the study.  
The sample cohort of this PhD study consists altogether of 356 families worldwide with 
diagnosed or suspected NM or a related muscle disorder (Figure 4). Study I includes the 
first 43 patient samples from 36 NM families that were studied using the NM-CGH array 
during the validation phase. This cohort is also included in the larger Study III that 
includes all the 266 samples from 196 NM families that had been studied using the NM-
CGH array. Study IV presents one family with a novel pathogenic variant in TPM3 that 
was identified among the studied 196 NM families using the NM-CGH array. Study II is a 
mutational update that presents all the 159 families that had been characterized with 
two pathogenic NEB variants using different methods from a cohort of altogether 309 
families. 
Figure 4. The number of studied families. 
This figure shows the number of studied 
families (n=356) with diagnosed or 
suspected NM or related muscle disorder 
in each publication (black numbers). All 
studies have samples shared with other 
studies (white numbers). Study III 
contains all the samples run by the NM-
CGH array, including also the samples of 
Studies I and IV. Study II presents all the 
families with both identified NEB 
mutations, overlapping with samples 
included in Studies I and III. 
Abbreviations: Fam=Families. 
The studied NM families are of different ethnic origin, including samples from Finland 
and other European countries, Asia, Australia, Africa, and America. The samples were 
received either as isolated DNA or as blood, cell lines, muscle, or skin biopsies from 
which DNA extraction was done using appropriate methods.  
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4.2. Control samples 
The NM-CGH validation (Study I) included four positive control samples from two NM 
families with previously-identified disease-causing NEB variants and five healthy control 
samples. In addition, one sample with a known variant in the TTN gene was used as a 
control. To date, 60 healthy control samples have been studied with the NM-CGH array. 
These anonymous control samples were received from the Finnish Red Cross and the 
Centre d’Etude du Polymorphisme Humain (CEPH). 
 
5. Methods 
The main methods that have been used in the different studies are summarized in Table 
4 and presented in more detail in the following chapters. 
Table 4. Methods used in the different studies  
 
 
 
 
Abbreviations: NM-CGH array=nemaline myopathy comparative genomic hybridization array, MLPA=multiplex 
ligation-dependent probe amplification, SSCP=single-stranded conformation polymorphism, dHPLC=denaturing 
high-performance liquid chromatography, RT-PCR=reverse transcription PCR. 
5.1. NM-CGH microarray 
The NM-CGH 8x60k microarray (Oxford Gene Technology IP Limited, Oxford, UK) was 
designed (Human reference sequence, GRCh37/Hg19) to target the causative genes for 
NM known at the time. The NM-CGH array version 1 was validated including the genes 
NEB, ACTA1, TPM3, TPM2, TNNT1, CFL2, KBTBD13 as well as the control gene TTN, 
encoding titin, densely covered with altogether ~53 000 probes. The 60mer 
oligonucleotide probes were designed to cover each of the genes including the exons, 
introns and exon-intron boundaries and ~25kb upstream and downstream of each gene. 
A tiling approach was used to achieve extremely high resolution for all the genes, albeit 
avoiding the most repetitive regions of these genes. In the NM-CGH array version 1 
there is one probe starting at every 10 bp interval. In version 2, the TTN control gene 
was removed and three new nemaline myopathy-associated genes were included; 
KLHL40, KLHL41, and LMOD3. Moreover, the probe interval was reduced from 10 bp to 
Method Studies
NM-CGH array I-IV
Whole-exome sequencing II, III, IV
MLPA I, II
SSCP / dHPLC + Sanger sequencing I-IV
PCR / RT-PCR + Sanger sequencing I-IV
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20 bp in the intronic regions for every gene except for NEB. No other significant 
modifications were made in the array update. In the NM-CGH array version 3, one novel 
putative NM gene, YBX3 (=CSDA), has been included. Detailed information of each gene 
is presented in Table 5. The remaining ~3 600 probes were spread across the entire 
genome to yield a low-resolution backbone to the array. The targeted oligonucleotides 
were designed as replicate pairs for every 60mer sequence. The replicates were not 
identical, as the first replicate was complementary to the forward and the other to the 
reverse strand of the target sequence. The replicate approach was used for increasing 
the reliability of aberration calling. An 8x60k array platform was chosen, where eight 
different samples can be analysed simultaneously with an identical design of 60 000 
probes on one array slide.  
The labelling, hybridization, scanning and analysis was done according to the 
manufacturer’s protocol (Oxford Gene Technology Ltd, Cytosure Genomic DNA labelling 
kit protocol, 8x60k format, version 1, 990097). The microarray was scanned using the 
Agilent DNA Microarray Scanner G2505C with 2 µm resolution, Agilent Scan Control 
version A.8.5.1 (Agilent Technologies Inc, Santa Clara, CA, USA), and normalised, filtered 
and further analysed in Feature Extraction software v10.7.3.1-12.0 (Agilent 
Technologies). The Cytosure Software v.3.4.9-v4.6.85 (Hg19) (Oxford Gene Technology 
Ltd) was used for graphic analysis of the data. The CBS (circular binary segmentation)  
Table 5. The coverage of the NM-CGH microarray. The genes (presented according to 
GRCh37/hg19) and the number of probes targeting each gene in the NM-CGH microarray 
design versions 1, 2 and 3.  
bp= base pair, Ctrl=control gene 
ACTA1 1q42 229 566 992 229 569 845 2 853 1 090 918 918
NEB 2q23.3 152 341 850 152 591 001 249 151 33 866 33 836 33 836
TPM3 1q21.3 154 127 784 154 167 124 39 340 5 604 3 808 3 808
TNNT1 19q13.42 55 644 162 55 660 606 16 444 1 700 1 254 1 254
TPM2 9p13.3 35 681 989 35 691 017 9 028 2 218 1 790 1 790
CFL2 14q13.1 35 179 593 35 183 896 4 303 1 282 1 162 1 162
KBTBD13 15q22.31 65 369 154 65 372 276 3 122 1 310 1 278 1 278
KLHL40 3p22.1 42 727 011 42 734 036 7 025 0 1 233 1 233
KLHL41 2q31.1 170 366 212 170 382 772 16 560 0 1 668 1 668
LMOD3 3p14.1 69 156 023 69 172 183 16 160 0 1 771 1 771
YBX3 12p13.2 10 851 812 10 875 911 24 099 0 0 2 452
TTN (Ctrl) 2q31.2 179 390 716 179 695 529 304 813 5 616 0 0
Total 692 898 52 686 48 718 51 170
Probe count 
Design 3
Length 
(bp)
Probe count 
Design 1
Probe count 
Design 2
Gene
Chromosomal 
region
Start (bp) Stop (bp)
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algorithm was used for CNV calling and specific thresholds determined to distinguish the 
calling of aberrations. The threshold of +0.03 or +0.04 was applied to duplications and 
threshold of -0.06 or -0.07 for deletions. A minimum of five to ten probes was used as a 
threshold for making a positive call for an aberration depending on the data quality. The 
targeted genes and the aberration calls were then manually checked.  
In addition to the custom NM-CGH microarray, the Cytosure ISCA+SNP 4x180k 
microarray (Oxford Gene Technology Ltd) was used for a couple of samples to study 
whole genomes including copy number variations and loss of heterozygosity (LOH). LOH 
regions larger than 10 Mb can be detected due to the SNP probes that are used on this 
array along with the CNV probes and visualized using the B-allele frequency plot. This 
method was used according to the manufacturer’s protocol (Cytosure Genomic DNA 
labelling kit protocol, 4x44k/4x180k format, version 1, 9900107) and analysed in the 
similar way as the NM-CGH array data. 
5.2. Whole-exome sequencing 
Exome capture and sequencing was done by OGT (Oxford Gene Technology Ltd, Oxford, 
UK) using the Agilent SureSelectXT All Exon 50Mb target enrichment kit (protocol v1.2; 
Agilent Technologies) on an Illumina HiSeq2000 platform using TruSeq v3 chemistry 
(Illumina Inc, San Diego, CA, USA). Exome analysis was completed using the OGT exome 
sequencing pipeline including the Burrows-Wheeler Aligner (BWA) package v.0.6.2 to 
map the reads to the human genome build 19 (hg19). Genome Analysis Tool Kit (GATK) 
v.1.6 was used to ensure a minimum number of the mismatches across the reads. Picard 
software versions 1.89-1.107 were used to mark duplicate reads likely to be resulting 
from PCR bias. BAM files were additionally processed with Samtools v.0.1.18. GATK was 
used for base quality scoring and indel variant calling. Variants were annotated with 
Ensembl data and dbSNP release 135 was used to determine novel SNPs. The data was 
then manually checked and Integrative Genomics Viewer (IGV) version 2.3.5 was used 
to visualize the data. Polyphen (Polymorphism Phenotyping) version 2 was used to 
predict possible impacts of an amino acid substitution on the structure and function of 
a protein, SIFT (Sorting Intolerant from Tolerant) was used to predict whether an amino 
acid substitution affects protein function and Condel (Consensus Deleteriousness score) 
to estimate the outcome of non-synonymous single nucleotide variants (Adzhubei et al., 
2010; Gonzalez-Perez and Lopez-Bigas, 2011; Ng and Henikoff, 2003).  
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5.3. Multiplex ligation-dependent probe amplification 
MLPA analyses were done targeting the NEB gene exons of interest with self-designed 
oligonucleotide probes using the MLPA SALSA kit according to the manufacturer’s 
protocol (MRC-Holland, Amsterdam, the Netherlands) as described in study I. The 
fragment separation and analysis was done using ABI-3730-XL DNA analyzer and the 
GeneMapper 4.0 software (Applied Biosystems, CA, USA). The final copy number 
analysis was done using Coffalyser v.7 software (MRC-Holland, Amsterdam, the 
Netherlands) or an in-house Excel-based software. 
5.4. Denaturing high-performance liquid chromatography 
The majority of the variant analyses with dHPLC had been done in our group prior to this 
thesis project. In this method, all NEB exons of a DNA sample, excluding the TRI region 
(exons 82-105), were amplified in 1-2 exon sets using PCR. The PCR samples were 
denatured and then slowly reannealed to form heteroduplexes and homoduplexes. The 
melting profiles of these duplexes were analysed using the Transgenomic WAVE Nucleic 
Acid Fragment Analysis System and the Navigator software (Transgenomic, San Jose, CA, 
USA) as previously described (Lehtokari et al., 2006).  
5.5. Sanger sequencing 
Until the year 2012 in our research group, Sanger sequencing was mainly used following 
aberrant SSCP or dHPLC screening results and later as an individual method where NEB 
exons were amplified in 1-2 exon sets. Sanger sequencing was performed on PCR or RT-
PCR products using an ABI-3730-XL DNA analyser (Applied Biosystems, Fosters City, CA, 
USA) and analysed using the Sequencher software versions 4.0-5.0 (Gene Codes 
corporation, Ann Arbor, USA) as previously described (Lehtokari et al., 2006). 
5.6. Bioinformatics methods 
Bioinformatic methods were used to analyse the breakpoints of the highly repetitive 
NEB TRI region. The data was analyzed using the GLAD package (Hupe et al., 2004) for 
the R environment (R Core Team, 2013) and the breakpoints and copy numbers were 
inferred using the daglad function. The resulting breakpoints, along with the original 
signal intensities and the genome annotations for the target region, were visualized 
using the GenomeGraphs (Durinck et al., 2009) and rtracklayer (Lawrence et al., 2009) 
packages.   
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RESULTS AND DISCUSSION 
6. New variant detection methods 
In this study, new variant detection methods have revealed several novel disease-
causing variants as well as mutation types causative of NM. The main focus was on the 
huge NEB gene in which we identified copy number variations, such as deletions and 
duplications, using the self-designed and validated NM-CGH microarray. Using whole-
exome sequencing (WES), we identified small variants including nonsense, missense and 
frameshift mutations. All pathogenic NEB variants are reported according to the 
reference sequence NM_001271208.1. The ACTA1 variants are marked according to the 
coding sequence of CR536516.1 and TPM3 variants according to the reference sequence 
NG_008621.1. The numbers of different novel pathogenic variants that have been 
identified using these novel methods in our group are summarized in Table 6. 
Table 6. Novel pathogenic variants identified using new methods. This table presents the 
number of different novel pathogenic variants and the number of nemaline myopathy families 
that they were identified in. Each different variant has been counted only once and the variants 
have been designated to the study in which they were been published for the first time.  
 
6.1. NM-CGH microarray (I-IV) 
When this study began, only one copy number variation, i.e. a mutation larger than 1 kb, 
had been characterized in NEB. The deletion of the entire NEB exon 55 was mainly found 
in the Ashkenazi Jewish population as a founder mutation (Anderson et al., 2004; 
Lehtokari et al., 2009). The number of NEB copy number variations is now steadily 
increasing as new methods, such as the NM-CGH microarray, enable much better 
detection of large variants. The Database of Genomic Variants (DGV) indicated a few 
copy number variations (CNV) in NEB, but these studies have mainly focused on finding 
CNVs on a genome-wide scale with different approaches and detection resolution (Alkan 
et al., 2009; Conrad et al., 2010; Perry et al., 2008). However, the incidence of these NEB 
Families Variants Families Variants
Study I 2 2 0 0
Study II 5 4 2 3
Study III 8 4 3 3
Study IV 1 1 0 0
Unpublished 2 2 2 3
Total 18 13 7 9
Published in
NM-CGH array Whole-exome sequencing
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variations and their possible phenotypic relevance remains unclear based on these 
control study groups. Therefore, a more focused study was initiated to elucidate this.  
A new custom tiling NM-CGH microarray platform was designed to target the known NM 
genes with a high resolution. The NM-CGH microarray was validated using the only 
previously known copy number variation, the deletion of NEB exon 55 (Anderson et al., 
2004). Using the NM-CGH array, an index patient affected with the intermediate form 
of NM (Family 105) was unambiguously shown to be homozygous and both parents 
heterozygous for this 2.5 kb NEB exon 55 deletion. The array profiles between the 
heterozygous and homozygous deletions were distinct. These results were verified using 
MLPA. (Study I) 
6.1.1. Novel pathogenic NEB copy number variations (I-III, U) 
To date, 266 samples from 196 NM families have been studied with the NM-CGH array. 
We have identified nine different novel copy number variations in NEB in ten different 
families. One of these novel variations was detected in two different families. All 
identified pathogenic variations are listed in Table 7 according to the size of the variant 
by NM-CGH. From the majority of families, samples only from the index patient with or 
without the parental samples were available. Each family is described in more detail 
below. 
Family 255 (sample 2553) had no previously identified mutations. To the best of our 
knowledge, this patient is the first one with NM with onset definitely in adulthood found 
to have a pathogenic variant in NEB. The NM-CGH array suggested a rather small 
deletion covering only a small part of the 3’ end of NEB exon 15 (Figure 5A). Sanger 
sequencing verified this mutation showing a 72 bp in-frame deletion in exon 15 
(c.1291_1362del) deleting 24 amino acids but the last amino acid of this exon is present 
in the sequence. This variation is interpreted as likely pathogenic because it deletes 
several amino acids and disrupts an actin-binding site. Parental samples were not 
available. In this patient, a second pathogenic NEB variant remains to be identified. This 
deletion is the smallest mutation identified by the NM-CGH array to date, and it is at the 
threshold of the method. It shows that in an optimal situation, this custom array is 
capable of detecting rather small copy number variations. (Study U)  
 
 
 46 
 
Table 7. The novel pathogenic NEB variants identified or further studied using the NM-CGH 
array
Abbreviations: bp=base pair, del=deletion, dup=duplication, ex=exon, int=intron, MLPA=multiplex ligation-dependent 
probe amplification, NM-CGH array=nemaline myopathy comparative genomic hybridization array, Sanger 
seq=Sanger sequencing, TRI= triplicate region of the nebulin gene, WES= whole-exome sequencing. 
Family 318 (sample 3183) had one previously identified disease-causing variant, a 
del_TCAA (c.24480_24483del; p.Gln8161fs) in NEB exon 173, causing a frameshift, 
inherited from the mother. The index case was affected by the typical form of NM. The 
NM-CGH array revealed a 0.9 kb deletion covering only a small part of the 3’ end of NEB 
exon 73 and most of intron 73 (c.10798_10872+839del) (Figure 5B), creating a 
truncating mutation. This was verified by Sanger sequencing, defining the mutation 
breakpoints and the deletion size as 914 bp. (Study II) 
Family 45 (sample 5451) was analysed to search for the second pathogenic NEB variant. 
The index case had the typical form of NM. There was a previously identified splice-site 
mutation in NEB intron 36 caused by an inversion (c.3987+1_+2inv) in the donor splice 
site (Lehtokari et al., 2006). NM-CGH analysis revealed a 1.1 kb deletion covering NEB 
exons 53-54 (c.6916-163_7431+211del) in the NM-CGH array profiles of the index case 
and the father (Figure 5C). The deletion of these two exons is most likely pathogenic. 
Family Patient Gene Aberration Exon Count Size (bp) Verification Breakpoint Study
F255 2553 NEB
ex 15 partly 
del
part of ex 
15 72 bp
PCR+ Sanger 
seq 
ex15 -> T-
microhomology ->ex15 U
F318 3183 NEB
ex 73 partly 
del
3' end of ex 
73 914 bp
PCR+ Sanger 
seq 
ex73 -> T-
microhomology ->int73 II
F45 5451 NEB ex 53-54 del 2 1084 bp
MLPA, PCR+ 
Sanger seq 
int52 -> AGCT-
microhomology ->int54 I, II
F211 2113 NEB ex 43-45 del 3 2.2 kb
PCR+ Sanger 
seq 
int42-> AT-
microhomology ->int45 II
F333 3333 NEB ex 43-45 del 3 2.2 kb
PCR+ Sanger 
seq 
int42-> AT-
microhomology ->int45 II, III
F321 3213 NEB
ex 69 partly-
71 del 
(+int65 
partly) 2+
4.2 kb del + 
110 bp ins
PCR+ Sanger 
seq 
ex69-> AATT-linker            
->int65…int65-> GG-
microhomology-> int71 III
F181 1813 NEB ex 1-24 del 24 53-64 kb MLPA
exact breakpoints 
unknown I, II
F309 3093# NEB
ex 1-51 dup 
(starts 5' of 
NEB ) 51
80 kb from 
NEB 
(minimum 
of 103 kb 
in total)
PCR+ Sanger 
seq int 51 
breakpoint,        
5' breakpoint 
under study
exact breakpoints 
unknown II
F396
3962, 
3963, 
3964 NEB
ex 14-81, 82-
105 del 68+TRI 88 kb MLPA, WES
exact breakpoints 
unknown U
F410 4103 NEB
ex 1-81, 82-
105 dup 81+TRI 133 kb
WES by group 
Laporte
exact breakpoints 
unknown II
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Even though Family 45 as well as Family 105, carrying the previously identified deletion 
of NEB exon 55 (Ashkenazi founder mutation), have deletion breakpoints in intron 54, 
they do not share an identical breakpoint. There is an approximately 1.7 kb distance 
between the two breakpoints in this intron. (Studies I, II) 
 
Figure 5. NM-CGH profiles of the NEB gene (on the left) and the zoomed aberrations (on the right) of 
five different nemaline myopathy patient samples. NEB is located in the reverse strand of the genomic 
DNA and therefore the exon numbering is ascending from right to left. The aberrations are marked with 
highlighting. A) Sample 2553 shows a 0.1 kb deletion in the 3’ end of NEB exon 15. B) Sample 3183 shows 
a 0.9 kb deletion including the 3’ end of NEB exon 73. C) Sample 5451 shows a 1 kb deletion covering the 
NEB exons 53-54. D) Sample 2113 shows a 2.2 kb deletion covering the NEB exons 43-45. E) Sample 3333 
shows a 2.2 kb deletion covering the NEB exons 43-45 and a loss of one copy in the 32 kb NEB TRI region.  
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Family 211 (sample 2113) was also analysed to search for the second disease-causing 
variant. The index case had the mild form of NM and a previously identified nonsense 
mutation in NEB exon 155 (c.22489C>T; p.Arg7497*), causing a premature stop codon. 
A 2.2 kb deletion covering NEB exons 43-45 was discovered using the NM-CGH array 
(c.5238+335_5764-407del) (Figure 5D). This was verified by Sanger sequencing that 
revealed the exact breakpoints of the deletion in introns 42 and 45 and gave the exact 
deletion size of 2249 bp. The deletion of these three exons is most likely pathogenic. 
Parental samples were not available for NM-CGH analysis. (Study II) 
Family 333 (sample 3333) had one previously identified pathogenic variant. The index 
patient had a mild form of NM with unusual features. He had started to have muscle 
pain and weakness at the age of two years, and weakness of the facial muscles was 
absent. The previously identified pathogenic variant was a frameshift mutation in NEB 
exon 130 (c.19992_19999dup; p.Asp6667fs). The NM-CGH array revealed a 2.2 kb 
mutation which was very similar to the one detected in family 211, a deletion covering 
exons 43-45 (c.5238+335_5764-407del) (Figure 5E). Sanger sequencing verified the 
mutations in these two families to be exactly the same. In addition, a deletion in the NEB 
TRI region was identified. This variation will be discussed in more detail in the next 
section covering the NEB TRI results (6.1.3). Parental samples were not available. 
(Studies II and III) 
Family 321 (sample 3213) had no previously identified pathogenic variants. The index 
case likely had the typical form of NM. The NM-CGH array revealed a ~4.1 kb deletion 
including exons 70-71 starting at the end of exon 69 or the beginning of intron 69 (Figure 
6A). However, Sanger sequencing revealed that this was not a simple deletion. The 
deletion turned out to cover 4.2 kb starting at the 3’ end of exon 69 and continuing with 
an AATT linker to intron 65. There is a 114 bp sequence from intron 65 after which the 
sequence continues normally from intron 71. The 114 bp duplication of intron 65 did not 
show on the NM-CGH array because of a gap between probes in this region due to an 
Alu repeat sequence. Parental samples were not available. In addition, a duplication of 
the NEB TRI was identified. This variation will be discussed in more detail in the next 
section covering the NEB TRI results (6.1.3). (Study III) 
Family 181 (sample 1813) was analysed to verify and further characterize the variation 
suspected based on the previous MLPA results. MLPA had indicated a large deletion in 
the 5’ end of NEB. The NM-CGH array revealed a large deletion of NEB exons 1-24 in the 
studied patient sample and the mother (Figure 6B). The size of the deletion lies 
somewhere between 53 and 64 kb. The exact breakpoints of this variation are difficult 
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to identify due to lack of probes, especially at the deletion breakpoint residing upstream 
of the 5’UTR of NEB. The mutated allele is lacking the promoter and is, thus, not 
transcribed. This family included two children affected with an unclassified form of NM 
Figure 6. NM-CGH profiles of the NEB gene (on the left) and the zoomed aberrations (on the right) of 
five different nemaline myopathy patient samples. NEB is located in the reverse strand of the genomic 
DNA and therefore the exon numbering is ascending from right to left. The aberrations are marked with 
highlighting. A) Sample 3213 shows a 4.1 kb deletion covering at least the NEB exons 70-71 and a gain of 
one copy in the 32 kb NEB TRI. B) Sample 1813 shows a 53-64 kb deletion covering the NEB exons 1-24. 
C) Sample 3093 shows a duplication covering the NEB exons 1-51 (80 kb), altogether the duplication covers 
>103 kb. D) Sample 3963 shows an 88 kb deletion covering the NEB exons 14-81 and a loss of one copy in 
the 32 kb NEB TRI. E) Sample 4103 shows a 133 kb duplication covering the NEB exons 1-81 and a gain of 
one copy in the 32 kb NEB TRI.   
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(clinical data lacking). Previously, a point mutation in NEB exon 129 had been identified 
(c.19913G>C), causing an amino acid shift (p.Arg6638Pro) (Lehtokari et al., 2006). This 
had not been inherited from the mother while a sample from the father was unavailable. 
(Studies I, II) 
Family 309 (sample 3093) had one previously identified disease-causing variant, a 
nonsense mutation in NEB exon 78 (c.11610C>A; p.Tyr3870*). This patient had a mild 
form of NM with unusual distribution of muscle weakness. The NM-CGH array identified 
a large duplication including NEB exons 1-51 (Figure 6C). The breakpoint in intron 51 was 
further characterized with Sanger sequencing to be in the proximity of nucleotide 
c.6807+573. However, the second breakpoint is located more than 25 kb upstream of 
the NEB gene and thus could not be identified with the NM-CGH array due to low probe 
density. This breakpoint and the orientation of the duplication are under further 
investigation. The size of this duplication may be much larger than can be estimated by 
the NM-CGH array. Parental samples were unavailable. (Study II) 
Family 396 (samples 3962, 3963 and 3964) had no previously identified disease-causing 
variants. The phenotype of the index patient (3964) was mild, with distal weakness as 
the presenting feature, which is atypical of NM. He was initially diagnosed as having 
tibial muscular dystrophy. However, on follow-up, the child was found to have a more 
generalized muscle weakness, with facial, bulbar and neck flexor weakness as well as 
weakness of the axial and distal limb muscles. There were also two other affected family 
members, the mother (3963) and maternal grandmother (3962) of the index patient, 
indicating autosomal dominant inheritance. The mother and grandmother presented 
later with mild distal weakness. The NM-CGH array showed in all of these three affected 
family members a large deletion in NEB including the exons 14-81 and continuing across 
the NEB TRI exons 81-105 (Figure 6D). This deletion was verified by MLPA. Other family 
members were studied and their NM-CGH profiles were normal. The cDNA study from 
the 3964 patient showed that there are heterozygous SNPs outside the deletion region 
of NEB suggesting that this mutated allele is expressed. Despite several attempts with 
different PCR primers and settings, PCR of the deleted allele has not been successful and 
thus, Sanger sequencing has not been possible. WES was done using the samples of the 
index patient (3964) and the mother (3963) but no additional pathogenic variants were 
identified in NEB. This is the first family that might indicate dominant inheritance of a 
disorder caused by a variant of the NEB gene. However, this variant and family warrant 
further investigation. (Study U) 
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Family 410 (sample 4103) had one previously identified splice-site mutation in NEB 
exon 129 (c.19944G>A). The phenotype of the index case was the distal form of core-
rod myopathy. The second variant required further investigations. The whole-exome 
sequencing previously done by our collaborators (Jocelyn Laporte /France) had 
indicated lower read depths in the 3’ end of NEB. In fact, the NM-CGH array showed that 
there was a duplication of NEB exons 1-81 continuing as a one-copy gain of NEB TRI 
exons 81-105 (Figure 6E). The estimated size of this duplication is 133 kb, not including 
the NEB TRI gain of one copy. The exact duplication breakpoints have remained 
unidentified. The size of this duplication makes it difficult to design appropriate PCR 
experiments. This duplication is the largest mutation identified thus far using the NM-
CGH array and it requires further investigation. (Study II) 
 
6.1.1.1. Breakpoints of the novel pathogenic NEB variations (I-III, U) 
The exact aberration breakpoints could be identified for 60% of the families (6/10) 
(F255, F318, F45, F211, F333 and F321) with novel aberrations in NEB. All the identified 
aberrations were deletions that had microhomology in the deletion breakpoints. The 
microhomology differed between 1-4 nucleotides (Table 7). This type of microhomology 
might indicate non-homologous end joining (NHEJ) or microhomology-mediated break-
induced replication (MMBIR) as the causative mechanism. Both of these mechanisms 
use microhomology in repairing DNA, and they may create aberrations in this repair 
process (Hastings et al., 2009; Liebert, 2008). Microhomology-mediated end joining 
(MMEJ) might also be a possible mechanism, but it usually involves longer stretches (5-
25 bp) of microhomology (McVey and Lee, 2008). Family 321 had a slightly more 
complex aberration, including an AATT-linker and insertion of additional sequence from 
a nearby intron 65 in the other breakpoint and a GG-microhomology at the other 
breakpoint. These multiple consecutive switches of template reading may indicate Fork 
Stalling and Template Switching (FoSTeS) or MMBIR as the causative mechanism. FoSTeS 
is thought to be mediated by microhomology of the original and invaded site and it is 
known to be capable of inducing complex rearrangements (Lee et al., 2007). On the 
other hand, MMBIR can also switch the template multiple times and it is also capable of 
inserting DNA sequence stretches from elsewhere to the repaired site, creating complex 
rearrangements (Hastings et al., 2009). On the other hand, the information scar of the 
additional AATT-linker could also suggest NHEJ (Shaw and Laski, 2004). However, these 
possible mechanisms behind the aberrations are currently hypotheses only, and require 
further investigations. Data regarding the different mechanisms is accumulating rapidly 
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and more samples are being analyzed in detail, which will help to elucidate the exact 
mechanisms behind these aberrations as well. (Study U) 
Four of the families (F181, F309, F396 and F410) with novel NEB aberrations have 
remained without characterization of the exact breakpoints thus far. Therefore, 
estimating the mechanisms behind these aberrations is difficult. The alterations include 
large deletions and duplications containing breakpoints that are difficult to study. Some 
breakpoints are embedded in sites of probe gaps in the NM-CGH array design. Inside the 
genes, the probe gaps mainly consist of sites of repetitive sequences. In addition, some 
aberrations extend outside the targeted gene regions. In these types of situations, the 
elucidation of the exact breakpoints is much more laborious with downstream analyses.  
In general, only a small part of the identified CNV breakpoints have been clarified to the 
single-nucleotide level in different studies thus far. Traditional PCR verification can be 
laborious, especially if no estimation of the CNV formation, such as the orientation of a 
duplicated segment is available. Even so, complex rearrangements can be extremely 
difficult to catch by traditional PCR methods. Genome-wide sequencing is possible for 
example using whole-genome NGS methods, but it is an expensive method to use only 
for verifying identified CNVs. Repetitive DNA poses its own difficulties that make PCR 
verification followed by sequencing very challenging. The PCR product itself can be 
difficult to obtain, and because sequencing is usually done in rather small segments 
(such as 300 bp) this makes studying of large duplications rather difficult. The 
breakpoints embedded in large repetitive segments will often remain unidentified 
(Conrad et al., 2010). Nevertheless, the study for deciphering the breakpoints of the 
identified novel NEB aberrations will continue. The characterization of these 
breakpoints may help to recognize some pattern in the aberration formation and 
possible sites exposed for mutations in the large nebulin gene. 
6.1.2. NEB triplicate region copy number variations (II, III) 
In addition to novel NEB variants, a frequent copy number variation of the NEB triplicate 
region (TRI) was identified using the NM-CGH array. The homologous NEB TRI region 
includes eight exons that are repeated three times (exons 82-89, 90-97, and 98-105). 
The normal copy number of the NEB TRI is thought to be six, i.e. three copies in each 
allele. The TRI variations were analyzed manually based on the logarithmic scale of the 
NM-CGH microarray results. Based on the results of patients and controls, it seems that 
deviations of one copy are tolerated but 2-4 copy gains might be pathogenic. 
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Of the 196 NM families studied with the NM-CGH array, 5% (9/196) showed a copy 
number loss (deletion) and 8% (16/196) a copy number gain (duplication) (Figures 5E 
and 6A) of NEB TRI. In addition, one family (F268) was identified including members with 
a gain, a loss, or a normal NEB TRI copy number (Figure 7). All in all, NEB TRI variations 
were identified in 13% of the NM families and in 10% of the control samples in our study 
cohort (Table 8). This makes NEB TRI the most common NEB variation characterized so 
far.  
All the identified losses in nine different NM families are deletions of one TRI copy (5/6 
copies present) and this aberration does not seem to segregate with the disorder. 
Moreover, the loss of one copy appears to be even more common in the studied control 
population. One-copy losses were identified in 8% of the control population samples 
(5/60) and in only 5% of the studied NM families (9/196). Five of the NM families have 
both disease-causing variants characterized, two families have one identified 
pathogenic NEB variant and two families remained without any being identified. The loss 
of one copy would cause an estimated 1458 bp shortening of NEB transcripts and a 486 
amino acid shortening of the translated protein, which corresponds to two nebulin super 
repeats (Donner et al., 2004). The two remaining TRI copies are estimated be enough 
for the allele to produce a functional protein. Many shorter transcripts of NEB are known 
to be produced in the normal muscle, and therefore, this alteration might not cause a 
drastic effect on the sarcomere thin actin filament structure.  
Among control samples, only one copy number gain (2%, 1/60) was identified. This 
sample showed a one-copy gain (7/6 copies present). Among NM families, copy number 
gains were much more common and contained gains of 1-4 additional copies.  
Table 8. Summary of NEB triplicate region (TRI) variations identified with the NM-CGH 
microarray in the NM family and control cohorts  
 
 
 
 
 
Abbreviations: NEB TRI=triplicate region of the nebulin gene, NM=nemaline myopathy, NM-CGH array=nemaline 
myopathy comparative genomic hybridization array. 
  NM tamiliesi Controls 
All 100 % (196) 100 % (60) 
NEB TRI variations 13.3 % (26) 10.0 % (6) 
Losses 4.6 % (9) 8.3 % (5) 
1 copy loss 4.6 % (9) 8.3 % (5) 
Gains 8.2 % (16) 1.7 % (1) 
1 copy gain 4.6 % (9) 1.7 % (1) 
2-4 copy gain 3.6 % (7) 0.0 % (0) 
losses and gains 0.5 % (1) 0.0 % (0) 
 54 
 
Approximately 5% (9/196) of the NM families harboured a gain of one additional TRI 
copy (7/6 copies present). This variant did not seem to segregate with the disorder. In 
one of these families (F335), the disease-causing variants had previously been identified 
in LMOD3 (Yuen et al., 2014). A pathogenic frameshift variant c.24475_24479dupCACAA 
was also identified in exon 173 of NEB, in another family (F407) segregating on the same 
allele as the TRI gain. The consanguineous healthy parents are both carriers of one TRI 
copy gain, as well as a NEB frameshift variant, and the patient is homozygous for both 
variants. One or both causative pathogenic variants remained unknown in the remaining 
seven families with a one-copy gain of the NEB TRI. Based on this data, it seems that 
deviations of one copy in a NEB allele, loss or gain, are tolerated. 
Furthermore, 4% of NM families (7/196) had patients with a gain of more than one TRI 
copy (8-10/6 copies present). All of these families had unidentified pathogenic 
variant(s), and where parental samples were available for analysis, this aberration 
seemed to segregate with the disorder. In addition, this type of aberration was not 
detected in the control population, however, the difference is not statistically significant 
(Fisher’s exact test). Moreover, three samples from patients with this type of NEB TRI 
gain were further tested using whole-exome sequencing. No further variants in NEB or 
any other NM gene were identified. One family (F268) is described here in more detail.  
Family 268: The index case 2683 (typical NM) has inherited a NEB TRI four-copy gain 
from the mother and a NEB exon 28 frameshift variant (c.2784delT) from the father. 
The unaffected father has a frameshift variant (c.2784delT) on one allele and a TRI 
deletion (one-copy loss) on the other allele, which supports the conclusion that one-
copy deletions of TRI would not be pathogenic. We suggest that the four-copy gain 
carried by the healthy mother, and inherited by the index patient, might be pathogenic 
(Figure 7). The pedigree shows that the NEB TRI gain segregates with the disorder, and 
only the combination of the NEB TRI gain and the frameshift variant result in the NM 
phenotype. Gains of more than one copy could disrupt the stability or secondary 
structure of the mRNA, and the transcription process, because of excess copies of the 
homologous region. In this case, no nebulin protein would be produced from this allele. 
If the transcription would work, the duplication would cause lengthening of the 
transcript and the nebulin protein. For example, a gain of four copies would add 5.8 kb 
to the mRNA and 1944 amino acids or eight super repeats to the protein. This could 
interrupt the normal repeat structure and disturb the interactions with the binding 
partners and also thin filament formation, especially if the duplications are inverted. 
We suggest that loss or gain of one NEB TRI copy would be benign, but deviations of 
more than one copy from the normal three copies in one allele may be pathogenic.  
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Figure 7. NM-CGH profiles of 
NEB in family 268. The index 
patient (C) (typical form of 
nemaline myopathy) has 
inherited a gain of the triplicate 
region of the nebulin gene (NEB 
TRI) from the mother (B) and a 
NEB (c.2784delT) frameshift 
mutation from the father (A) (not 
shown in the NM-CGH array). The 
father (A) and two siblings (E, F) 
have a one-copy deletion and 
one brother (D) the normal copy 
number of NEB TRI. The index 
patient has the typical form of 
NM and all other family members 
are unaffected. The family 
pedigree is shown in Figure 7G.  
Figure 7 is reprinted and modified with 
the permission of the copyright owner: 
Kiiski et al, 2015, Eur J Hum Genet. 
doi:10.1038/ejhg.2015.166.         
Licensee the Nature Publishing Group.  
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6.1.2.1. Breakpoints of the NEB triplicate region copy number variations (III) 
The breakpoints of the TRI variations are difficult to characterize. The breakpoint 
analyses of two samples 526 (F2) with a one-copy loss and sample 2721 (F272) with a 
four-copy gain are shown in Figure 8A-B. In the normal situation, the whole TRI region 
size is ~32 kb and gains would only make this region larger, as each gain would add 
~10 kb. The one-copy losses would settle the region around 20 kb. The repetitiveness 
and homology of the TRI region have proven to be very challenging especially for PCR 
studies. The last introns of each TRI repeat (introns 89, 97, and 105) contain repetitive 
elements, such as Alu and LINE repeats. These transposable elements are known to be 
capable of being involved in NAHR (non-allelic homologous recombination) that is  
Figure 8A-B. Breakpoint analysis of NEB TRI copy number loss and gain. Sample 526 from family 2 shows 
a one-copy loss (A) and sample 2721 from family 272 a four-copy gain (B) of the NEB TRI. Breakpoint 
analysis shows repeat elements in the breakpoint regions. In the upper part of the figure, the inferred 
breakpoints are shown with red vertical lines and the inferred copy number of the corresponding 
fragment is indicated with blue horizontal lines. The tracks in the lower part of the figure show the 
different repeat elements, the NEB triplicate region and the gene structure. Abbreviations: DNA=DNA 
repeat elements, LTR=long terminal repeats, Low Compl=Low complexity DNA sequences, SSR=Simple 
sequence repeats=microsatellite DNA. Figure 8A-B is reprinted and modified with the permission of the copyright owner: 
Kiiski et al, 2015, Eur J Hum Genet. doi:10.1038/ejhg.2015.166. Licensee the Nature Publishing Group.  
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thought to be the most common underlying mechanism for recurrent CNVs (Gu et al., 
2008; Kolomietz et al., 2002). Several studies have suggested that Alu repeats could also 
mediate chromosomal rearrangements via non-homologous mechanisms such NHEJ, 
FosTeS, or MMBIR (Shaw and Lupski, 2005; Vissers et al., 2009). The lack of further 
information on these TRI variations makes it difficult to estimate the exact causative 
mechanism. Viewing it from an evolutionary aspect, the human NEB TRI region is 
thought to have emerged from two duplication events (Bjorklund et al., 2010). For 
example, the mouse Neb includes only one copy of this eight-exon set and is lacking the 
LINE-L2 elements. Precisely these different repeat elements might explain the 
susceptibility of the human NEB TRI region to recurrent copy number changes, making 
this the most common variant characterized in NEB to date. 
 
6.1.3. A novel pathogenic TPM3 variant (IV) 
In addition to NEB variants, one variation was identified in another NM gene, using the 
NM-CGH array. This is a pathogenic homozygous deletion affecting TPM3, identified in 
one NM family (F366). 
Family 366 (sample 3663) had one previously identified pathogenic variant in NEB 
exon 42 (c.5060G>A; p.W1687X). The index case had the severe form of NM and 
deceased at the age of 17.5 months. Muscle biopsy at five months showed myopathic 
features with abnormal variation in fibre size. The Gömöri trichrome stain identified red-
staining inclusions in several fibres, which electron microscopy confirmed as nemaline 
rods. The NM-CGH array showed a 17-20 kb deletion region in TPM3. The deletion region 
was first interpreted as two deletions separated by a normal region in between, but 
using the specific settings created for GC rich probes in the Cytosure analysis software, 
the results indicated that this was indeed one single deletion, according to HGVS 
nomenclature (Human Genome Variation Society) a homozygous deletion of hg19 
chr1:g.(154,156,325_154,156,028)_(154,173,059_154,177,712). This homozygous 
deletion removes the promoter and the exons 1a and 2b of TPM3 from both alleles 
(Figure 9). However, based on the NM-CGH array and Sanger sequencing, TPM3 exon 1b 
and its promoter are present, indicating that the non-muscle isoforms are expressed. 
This is most likely the case as non-muscle isoforms of TPM3 are essential for embryonic 
development (Hook et al., 2004). 
The deletion also covers a micro-RNA encoding gene, MIR190B and the last two exons 
of the C1orf189 gene. The role of miR-190b and the uncharacterized protein C1orf189 
in skeletal muscle, if any, is unknown. The deletion starts upstream of the TPM3 gene 
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and the breakpoint resides in a 4.7 kb region that is lacking probes, because this region 
contains various Alu sequence repeats hindering the designing of unique probes. The 
identification of the exact breakpoints by PCR and sequencing has not been successful 
so far which means that the mechanism behind this mutation is difficult to determine. 
Further experiments are ongoing to resolve this. 
This sample has also been studied with whole-exome sequencing, which failed to detect 
any new causative variants in the known NM genes, but verified the NM-CGH results 
and the previously identified nonsense variant in NEB exon 42. This reinforces the 
interpretation that the homozygous TPM3 variation is most likely the causative 
mutation in this patient. Because both the promoter and exon 1a are deleted from both 
alleles, we presume that the muscle-specific TPM3 isoform could not be produced.  
One patient with severe NM has previously been characterized with a homozygous 
nonsense mutation in the muscle-specific exon 1a of TPM3. The authors hypothesized 
that either no TPM3 peptide would be produced from the mutant allele due to instability 
of the mutant mRNA, or, if a truncated peptide was produced, it could act as a dominant 
negative protein, preventing proper formation of the tropomyosin polymer 
 
Figure 9. NM-CGH array profile of the TPM3 gene. NM patient 3663 shows a 17-20 kb homozygous 
deletion in chromosome region 1q21.3 covering the promoter and the exons 1a and 2b of TPM3, MIR190B 
as well as the last two exons of C1orf189. Note the different Y axis scale compared with the previous 
figures due to the homozygous deletion. The genes, exons and their orientation are indicated in the lower 
part of the figure. The exons expressed in all TPM3 isoforms are marked with dark blue, exons not 
expressed in striated muscle are marked with white and alternatively spliced exons present in the striated 
muscle isoform are marked with pale blue colour. Figure 9 is reprinted and modified with the permission of the copyright 
owner: Kiiski et al, 2015, J Neuromuscul Dis. 2015 doi: 10.3233/JND-150107. Licensee the IOS Press Copyright. 
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chain (Tan et al., 1999). Even though the mutational mechanism in this case is different, 
we hypothesize that the outcome is the same, i.e. a null state for the muscle-specific 
isoform. Parental samples were not available for analysis but the existing information 
on the parents suggested consanguinity. This was further shown using whole-genome 
SNP array, in which the DNA sample of the index patient indicated loss of heterozygosity 
(LOH) for many regions of the genome including TPM3 in chromosome region 1q21.3, 
but not for NEB in chromosome region 2q23.3. This explains why the deletion in TPM3 
is homozygous but the variant in NEB exon 42 is heterozygous.  
In conclusion, as this TPM3 deletion is the only large CNV identified in a gene other than 
NEB, large copy number variations in other known NM genes are likely a very rare cause 
of NM. In our data cohort this kind of aberration was encountered in only one family out 
of 196 (0.5%). However, the possibility of such large aberrations still needs to be taken 
into consideration. 
6.1.4. Features of the NM-CGH array (I-IV) 
One of the advantages of a custom CGH microarray is flexibility. This method allows 
choosing any genes of interest to be analysed in a single experiment. Regarding the NM-
CGH array this allows the simultaneous analysis of all NM-causing genes. In addition, the 
gene content of the microarray is available for modifications. This is useful, for example, 
when new genes are identified. In the first modification, three novel genes (KLHL40, 
KLHL41 and LMOD3), and in the second modification, a novel putative NM gene (YBX3) 
were added to the NM-CGH microarray platform. However, positive controls are often 
unavailable for the testing of these novel genes due to lack of previously identified CNVs 
in them. The verification is then based on analysing the performance of the probes in 
general in these newly added genes. The field of NM research is undergoing fast 
development and the NM-CGH array will be updated when new NM genes are identified. 
Consequently, samples that have been analysed with a previous array version, need to 
be subsequently analysed for the novel genes or analysed again with an updated array 
version. In addition to the flexibility of the array content, the NM-CGH method is fast 
and cost-efficient, and it requires a rather low quantity of DNA (500-1000 ng) per 
sample.  
As the probes used on this array are 60mer long oligonucleotides, this method is not 
able to detect very small aberrations. The theoretical functional resolution of the NM-
CGH array allows the detection of aberrations as small as 100-150 bp in the regions with 
optimal tiling resolution, one probe starting every 10 bp and 5-10 consecutive probes 
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used as an aberration threshold. However, the smallest mutation detected by the NM-
CGH array so far is even smaller, a deletion of 72 bp inside NEB exon 15, which was 
verified with another method. This mutation is definitely at the detection threshold of 
the method, and it was identified comparing this aberration with the in-house 
aberration database, the data for which were gathered during this project. However, we 
classify this as a CNV, even though the size is smaller than typically defined as the 
minimum size of a CNV, ~1 kb (Redon et al., 2006). This shows that in an optimal 
situation, the NM-CGH custom tiling design allows for the identification of very small 
copy number variations, much smaller compared with conventional whole-genome 
arrays.  
Despite the tiling approach and the very high resolution of the NM-CGH microarray, the 
method does not always reveal the breakpoints of the identified aberrations very 
precisely, as they may reside in regions of repetitive sequence or outside the targeted 
genes. Properly functioning unique probes cannot be designed targeting repetitive 
sequences and therefore some gaps without any probes remain in the design. Different 
sequencing methods can be used to further map the exact breakpoints of these 
particular aberrations.  
The breakpoints fairly often reside in these regions that are lacking probes, i.e. repetitive 
sequences. It is known that repetitive sequences can predispose for rearrangements and 
copy number aberrations. We hypothesize that this might be the case for some of the 
detected pathogenic variants and NEB TRI variations. Further studies are ongoing to 
elucidate this. 
6.2. Whole-exome sequencing (II-IV, U) 
Whole-exome sequencing (WES) is the most recent addition to the variant analysis 
methods used in this study. This part of the project is currently in its early stages. 
However, samples from ten NM patients who had remained without identification of 
one or both pathogenic variants, have been studied. Thus far, we have identified novel 
pathogenic variants in known NM genes for six of the ten studied families using WES. 
The identified mutations are summarized in Table 9. Furthermore, we have identified 
two novel variants in a putative NM gene, YBX3, in one NM family. These variants were 
shown to segregate with the disorder and the potential pathogenicity of the variants is 
currently being investigated further. In addition, four samples with two identified 
variants were tested. This included three samples with putative pathogenic NEB TRI copy 
Novel pathogenic variants in the NM genes (II-III) number gains (section 6.1.3) and 
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sample 3663 with the novel TPM3 deletion (6.1.5). Using WES, no additional pathogenic 
variants were identified in these samples. 
Family 2 (sample 523) includes two siblings with typical NM. One disease-causing variant 
had been identified previously, a missense mutation in NEB intron 122 (c.19097G>T). 
This was verified with Sanger sequencing and it had been inherited from the mother. 
We studied the sample of one affected family member using WES and identified a splice-
site variant (c.508-7T>A) in NEB intron 7. This creates a novel acceptor splice site 
inserting five nucleotides, leading to a frameshift p.Val170fs. The variant was verified 
using Sanger sequencing which showed it to be inherited from the father. The effect of 
the variant on pre-mRNA splicing was verified using a NEB minigene construct. (Study 
III) 
Family 4 (sample 545) includes a sibling pair with typical NM. Pathogenic variants had 
not been identified previously, even though the whole NEB gene had been screened 
using dHPLC. We studied one affected family member with WES and identified a splice- 
site mutation in NEB intron 65 (c.9414+1G>T) and a missense mutation in NEB exon 61 
(c.8381A>T; p.Tyr2794Phe). These were verified with Sanger sequencing and the splice- 
site mutation had been inherited from the father and the missense mutation from the 
mother. The missense mutation disrupts an actin-binding site. (Study II) 
Table 9. Variants in the NM families studied by whole-exome sequencing. The previously 
identified variants were detected using dHPLC, Sanger sequencing or the NM-CGH array. After 
these analyses, whole-exome sequencing (WES) revealed yet novel variants for 6/10 of the 
studied NM families. The allele frequencies in the ExAC database are reported. Reference 
sequences NEB: NM_001271208.1, ACTA1: CR536516.1.  
Abbreviations: A=published in Lehtokari et al. 2006, ExAC database=Exome Aggregation Consortium Browser 
Database, (F)=inherited from the father, (M)=inherited from the mother, NA=not available, NEB TRI=triplicate region 
of the nebulin gene. 
Family Patient
Variants identified using NM-
CGH array, SSCP/dHPLC+Sanger 
sequencing
Detected 
using 
WES
Allele 
frequency 
in ExAC 
Variants identified using whole-
exome sequencing
Allele 
frequency 
in ExAC Study
NEB  exon 122 c.19097G>T (M) 
A yes 0.00008935
NEB TRI loss (5/6 copies) (F) no NA NEB  intron7, c.508-7T>A (F) NA
- NEB  intron 65, c.9414+1G>T (M) NA
NEB  exon 61, c.8381A>T (F) 0.00001665
NEB  intron 35, c.3879+1G>A (M) 0.00002583
NEB exon 156, c.22746delG (F) 
A
yes NA
- ACTA1  intron 6, c.990+1G>T (M) 0.000008244
ACTA1 intron 6, c.990+1G>T (F) 0.000008244
NEB TRI gain (7/6 copies) (M) no NA NEB  exon 173, c.24475_24479dup (M) NA
NEB  TRI gain (7/6 copies) (F) no NA NEB  exon 173, c.24475_24479dup (F) NA
NEB TRI loss (5/6 copies) (M),                  
NEB  exon 86; c.13134delA (M)
no            
no
NA
NEB exon 172, c.24372_24375del (F) 0.00002915
U
III
4113F411 III
5163
4073
F2
F4
F6
F16
F407
III
II
523
545
564 II
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Family 6 (Sample 564) includes a pair of siblings affected with typical NM. Previously, a 
delG causing a frameshift mutation in NEB ex 156 (c.22746del; p.Met7582Ilefs*5) had 
been identified by SSCP and sequencing. This had been inherited from the healthy 
father. We identified the second pathogenic variant with WES. This was an essential 
splice-site mutation in NEB intron 35 (c.3879+1G>A) inherited from the mother. This 
variant was verified with Sanger sequencing. (Study II)  
Family 16 (sample 5163) had a sibling pair affected with severe NM and no previously 
identified disease-causing variants. We studied the sample of one affected child and 
identified a homozygous essential splice-site mutation in ACTA1, at the donor splice site 
of intron 6, c.990+1G>T (GenBank CR536516.1). This is a pathogenic variant interpreted 
to have caused the nemaline myopathy in this patient. (Study U)  
Family 407 (sample 4073) had two siblings affected with severe NM. There were no 
previous pathogenic variants except a gain of NEB TRI (8/6 copies) that was inherited 
from both parents, who had one gained TRI copy each (7/6 copies). We studied the 
sample of one affected child and identified a homozygous CACAA insertion in NEB exon 
173 (c.24475_24479dup). This was verified by Sanger sequencing. (Study III)  
Family 411 (sample 4113) includes a child with typical NM. No previous disease-causing 
variants had been identified, except a loss of NEB TRI (5/6 copies), detected by the NM-
CGH array, that had been inherited from the mother (5/6 copies). Using WES, we 
identified a deletion of four nucleotides in NEB exon 172, delAAGA, (c.24372_24375del) 
that was shown with Sanger sequencing to have been inherited from the father. After 
WES, the NEB TRI exons were further studied using Sanger sequencing, because this 
region is not covered in WES. A frameshift mutation in NEB exon 86 was identified 
(c.13134delA). (Study III) 
Families 2, 4, 6, and 16 had been previously studied for NEB and ACTA1 variants, but 
these splice-site and missense mutations had remained unidentified. This is mostly due 
to the previously used analysis methods. For example, families 4, 6, and 16 had been 
screened for NEB variants with SSCP and dHPLC but these did not indicate any change 
in the sequences (this data was checked again after the WES finding). Therefore these 
regions had not been Sanger sequenced. The formation of the novel splice site in intron 
7 of NEB had been missed in the analysis of family 2 when Sanger sequenced. This 
emphasizes that even though a family would have been studied for NM gene variants 
previously, this does not exclude the possibility of finding mutations in these genes with 
more efficient methods.  
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6.2.1. Novel putative disease-causing variants outside the known NM genes (U) 
In addition to these characterized pathogenic variants in the known NM genes, two 
variants were identified in one family (F361) in a novel putative NM gene, YBX3, 
encoding Cold-Shock Domain Protein A. The patient whose NM has been assigned to the 
category ‘other forms of NM’ was shown to carry compound heterozygous missense 
variants in conserved sites of this gene; p.Ser34Arg, of which no allele frequency was 
available in ExAC (poor coverage in exome data) and p.Arg129Trp with an allele 
frequency of 0.00005766 in the ExAC database (protein reference sequence 
AAH15913.1). YBX3 is highly expressed in skeletal muscle (Kudo et al., 1995). YBX3 
variants have not been previously associated with NM but these variants may turn out 
to be the disease-causing mutations in this family. Further investigations are ongoing to 
resolve this.  
This, in particular, shows the potential of whole-exome sequencing. All the known NM 
genes can be studied at once, and with better detection rate than before. Furthermore, 
the method allows all other genes of the genome to be studied as well. This is important 
because so many NM families have been extensively studied with a number of different 
methods and still one or both disease-causing variants may have remained unidentified. 
This implies that there still are additional NM genes to be discovered. In this perspective, 
WES is the logical and most potential method of choice, as it does not require previous 
knowledge of any potential novel genes. However, the interpretation of WES results 
requires experience to be able to infer whether a finding is a benign polymorphism or 
pathogenic variation. 
With next-generation sequencing techniques becoming more common in the diagnostic 
field, it is worth noting that no technique alone reveals all variants, especially of the 
gigantic nebulin gene. There are regions in NEB that are not covered in adequate reading 
depths, and regions of great homology and repetitiveness that cause difficulties in 
sequencing. For example, most of the intronic variants and some copy number 
variations would be missed using WES alone. Specifically, the NEB triplicate region 
appears to be missing from the exome-sequencing kits, because of the great homology 
of the region. However, small variants in the TRI region have been identified using 
Sanger sequencing of single TRI exons, and copy number variants of the entire NEB 
triplicate region have been identified with the NM-CGH microarray. This is why the NM- 
CGH microarray and exome sequencing methods complement each other well in NM 
diagnostics and research.  
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7. NEB variants causing nemaline myopathy 
7.1. NEB mutation update (I-III) 
To date, both pathogenic NEB variants have been identified for 165 different NM 
families, including 220 different mutations. The number of NM families included in each 
study and their status regarding the number of identified pathogenic NEB variants at the 
time of publication of each study is presented in Table 10. In addition to these NEB 
variants, disease-causing variants were identified in other NM genes in 15 families. In 
one family, pathogenic variants were identified in TPM3, in five in ACTA1, in three in 
LMOD3, while six families showed pathogenic variants in KLHL40. 
Counting each different 220 NEB variant only once, the most common types of 
pathogenic variants are splice-site mutations (33%) and small deletions or insertions 
(<20 bp) (33%), mostly causing a frameshift, but also one in-frame mutation. The third 
most common are nonsense mutations (22%). Missense mutations account for 7% of 
the disease-causing variants. Only those missense mutations affecting nebulin-actin or 
nebulin-tropomyosin interactions were interpreted as pathogenic. Various types of copy 
number variations, i.e. large deletions or duplications, constitute the rarest group (5%) 
(Figure 10A); however, the occurrence of copy number variations was found to be much 
more common than previously estimated. Viewing the data on the 165 NM families in 
which two pathogenic NEB variants have been identified, no less than 16% of the 
families (26/165) had a pathogenic CNV. This shows that even though the different CNVs 
are rather rare per se, some of them are recurrent, such as the exon 55 deletion and 
NEB triplicate region variations, making pathogenic CNVs a rather frequent finding 
among NM families. 
The great majority (84%) of families (138/165) are compound heterozygous for two 
different mutations. Furthermore, 41% of families (67/165) have their own two unique 
mutations that are not shared with any other family. However, there are four different 
Table 10. The number of nemaline myopathy families with both, one and no identified 
pathogenic NEB variants in each study  
 
 
 
 
Study NM Families 2xNEB 1xNEB 0xNEB
study I 36 2 20 14
study II 309 159 58 92
study III 196 36 50 110
study IV 1 1 homozygous deletion in TPM3
Tot 356
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variants in our data set which may be regarded as founder mutations. The most common 
one is the Ashkenazi Jewish founder mutation deleting the 2.5 kb region including 
exon 55 (Anderson et al., 2004; Lehtokari et al., 2006; Lehtokari et al., 2009) that was 
identified in 13 families in this study. Moreover, there are three different variants 
identified in Finnish families that may be regarded as founder mutations. These are a 
missense mutation in exon 122 (p.Ser6366Ile), another missense mutation in exon 151 
(p.Thr7417Pro), and a frameshift mutation in exon 122 (p.Thr6350Profs*4) identified in 
eleven, five, and two families, respectively. In addition to the founder mutations, there 
were 11 different pathogenic variants shared between three or more families, and 26 
different mutations shared between two families. These families share one mutation, 
but carry a separate second mutation. The haplotyping results show that the Finnish 
 
Figure 10. A) The Distribution of Different Types of Pathogenic NEB Variants. Counting each different 
pathogenic NEB variant once, the most common types of variants are splice-site and small indel mutations 
followed by nonsense and missense mutations. Large copy number variations are the rarest. B) The 
Clinical Entities Caused by NEB Mutations. NEB variants most commonly cause typical NM, then severe, 
intermediate and most rarely mild NM. In addition it causes other forms of NM, and NM-related disorders. 
For a fifth of the patients clinical data was not available to determine the form of NM. Abbreviations: 
indel=insertion/deletion. 
 66 
 
families sharing a certain pathogenic NEB variant also have the same haplotype. This is 
also the case regarding the NEB exon 55 deletion. Some of the remaining shared 
pathogenic variants in NEB seem to be recurrent, whereas others have a common 
ancestral haplotype.  Only one location in NEB is considered to be a mutational hotspot, 
i.e. the donor splice site of intron 32, including nucleotides c.3255+1 and c.3255+2, that 
were mutated in altogether 10% of families in this study cohort (17/165).   
7.2. Genotype-phenotype correlations (I-III) 
Among the families with two identified NEB mutations, sufficient clinical data has been 
provided for 149 families  to be able to determine the NM form of the patients (including 
143 families from studies I and II, and 6 families from study III): 25 families included 
patients with severe NM, 15 with intermediate, 53 with typical, 8 with mild, and 20 with 
“other forms” of NM (in four families there were siblings that had either the typical or 
the intermediate form of NM) (Figure 10B). 
Finding genotype-phenotype correlations in NM patients with NEB mutations proved to 
be more difficult than originally thought. Although the number of NEB mutations is now 
substantial, a statistically significant genotype-phenotype correlation between the type 
of mutation and the NM subtypes was unobtainable. First of all, statistical data analysis 
requires that the NM families are grouped into different categories. As most families 
have two private mutations, there is no simple and correct way to do this. The clinical 
heterogeneity of NM is underlined by the fact that even affected family members 
sharing the same mutations may present different forms of the disease.  
Some interesting phenotypic findings were made: for example, some of the families that 
had mutations in the alternatively spliced exons of NEB (exons 63-66, 143-144, and 167-
177) had exceptional clinical/histological features and they were thus all assigned to the 
group “other forms of NM”. Three out of six families (Families F270, F284 and F386) with 
pathogenic variants in exons 63-66 included patients with pronounced weakness of axial 
muscles, with relative sparing of limb muscles. Usually the axial, and the proximal limb 
muscles, and later the distal limb muscles are involved in patients with NM. Regarding 
the alternatively spliced exons 143 and 144, one adult sib pair (Family 187) had a 
pathogenic variant in exon 143, and they both had ophthalmoplegia, which is very 
unusual in NM. Family 390 had a truncating mutation in exon 144 and showed atypical 
dystrophic biopsy features and normal strength of the neck flexors, which are almost 
always weak in NM. Some of the patients with mutations of the alternatively spliced 
exons 167-177 had fasciculations, selective axial weakness, rigid neck and/or spine, or 
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other atypical features of NM. We hypothesize that these atypical findings may reflect 
some tissue- or muscle-specific functions of the alternatively spliced exons that are 
currently unknown. However, more data is needed to draw conclusions on this matter. 
7.3. Mutation frequency (II) 
Exome Variant Server (http://evs.gs.washington.edu/EVS/) data was searched for 
information about NEB variants in the general population. This databank included 
exome-sequencing data of 6503 DNA samples from individuals of African American and 
European American origin with no known neuromuscular disorders. The data contained 
1295 variants in the NEB coding region and conserved splice sites (February 2014). These 
included benign missense variants, intronic variants, synonymous changes etc. 
However, 69 individuals of those approximately 6000 individuals whose samples were 
successfully exome sequenced, were heterozygous carriers of a pathogenic NEB variant. 
The carrier frequency was thus 1/87, yielding a disease incidence of approximately 1 in 
30,000 for autosomal recessive myopathies caused by pathogenic NEB variants. The 
large ExAC database was not publicly available at the time of this study. Currently, 
individual variations of the nebulin gene can be searched for in the ExAC database. 
However, due to the large size of the gene, the database does not enable studying the 
entire NEB gene all at once. 
Nemaline myopathy caused by NEB variants seems unexpectedly uncommon compared 
with the estimated mutation rate of the genome, and the size of the NEB gene (249 kb 
of genomic sequence). Moreover, it has been shown that there are other important 
factors affecting the mutability of a certain gene, such as the local sequence context 
(Samocha et al., 2014). This may partly explain the observation that NEB tolerates 
mutations well. Moreover, patients with severe NM who die at birth or soon after, may 
be left undiagnosed. Additionally, pathogenic NEB variants can also cause other NM-
related disorders, such as distal myopathies. These disorders may be milder and thus 
underdiagnosed. Overall, most of the missense mutations are not, in fact, pathogenic 
variants. We propose that only if the missense mutation is located in a conserved 
binding site, such as a nebulin-actin or nebulin-tropomyosin binding site, it should be 
regarded as a pathogenic variant (Lehtokari et al., 2014; Marttila et al., 2014). This could 
explain why mutations in such a large gene result in such rare disorders. 
 
  
 68 
 
CONCLUSIONS AND FUTURE PROSPECTS 
In this Doctoral Thesis study, a novel variant detection method was developed for genes 
causative of nemaline myopathy. Currently, the molecular genetic verification of a 
clinical and histological diagnosis of NM is cumbersome due to the lack of one specific 
method for this. Using a combination of different methods has turned out to be a 
necessity for identifying the large variety of pathogenic variants in the NM genes. The 
importance of studying NEB variants is underlined by the fact that pathogenic NEB 
variants are by far the most common cause of recessively inherited NM, probably also 
the most common cause of NM in general. Furthermore NM is one of the most common 
congenital myopathies.  
In this study, a new custom targeted tiling NM-CGH microarray was designed which 
revealed copy number variations in the NM-causing genes in the study cohort of 196 
NM families. In ten different families, nine novel disease-causing variations were 
identified in NEB in ten different families. Furthermore, a recurrent copy number change 
of the NEB triplicate region was found in 13% of the NM families (26/196) and the NEB 
triplicate region CNV was interpreted to be possibly pathogenic in 4% of the NM families 
(8/196). In addition, a novel pathogenic homozygous deletion was found in another NM 
gene, TPM3, in one family. All in all, the NM-CGH array is quick and cost-effective, and 
it has revealed large novel disease-causing or putative pathogenic copy number 
variations in altogether 10% of the studied NM families (19/196). New samples that are 
sent to our group for mutation analysis are currently first tested with the NM-CGH array, 
and the downstream methods are chosen depending on the array findings.  
Further studies are ongoing to decipher the exact breakpoints of each copy number 
variation, especially for the NEB TRI region. For this, testing has commenced on a fourth-
generation sequencing technique: Nanopore sequencing of genomic DNA, using the 
MinION platform that does not require PCR. In addition, functional analyses are needed 
in order to determine the consequences of the changes at the protein level. This will 
help to resolve the molecular mechanisms as well as the potential pathogenicity of some 
of the recurrent NEB TRI variations. 
Whole-exome sequencing (WES) has made its way to diagnostics and it has proven to 
be efficient in identifying novel disease-causing variants. It allows for studying the 
known NM genes as well as most of the other genes of the exome in a single experiment. 
Novel pathogenic variants in the known NM genes were identified in approximately half 
of the studied families (6/10). In addition, one family was identified with two variants in 
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a novel, putative NM gene, YBX3. These variants were shown to segregate with the 
disease in the family and functional studies are ongoing.  
Despite the indisputable advantages of WES, even this method is unable to detect all 
types of variants. For example, NEB TRI and other regions of great homology are not 
covered by exome sequencing kits because of lack of unique DNA sequence in those 
regions. Thus, the NM-CGH microarray and WES methods complement each other well 
in NM diagnostics. 
A total of 165 patient families have now been identified with two pathogenic NEB 
variants. The majority (84%) of the families are compound heterozygous for two 
different NEB pathogenic variants. When counting each different mutation only once, 
the most common type of mutations in this cohort are splice-site mutations (33%) and 
small indels (33%), followed by nonsense (22%) and missense mutations (7%). Various 
large mutations are rare (5%), however, more common than previously thought. 
Moreover, among these 165 NM families with two pathogenic NEB variants, in a total of 
16% (26/165), one of the mutations identified was a pathogenic copy number variation. 
It has become evident that it is extremely difficult to discern any detailed genotype-
phenotype correlations in NEB-caused NM, even considering the now large number of 
patients with clarified genotypes. Patients sharing the same pathogenic variants may 
have different disease severities, even within the same family. Thus, the identified 
variants may not be the only factors determining the severity of the disease. Modifying 
genetic factors might play a role in the severity of the phenotype. These are currently 
being revealed by the use of new techniques such as exome and whole-genome 
sequencing. Furthermore, epigenetics and environmental factors play a role in 
modifying our genome, making genotype-phenotype correlations more complex. 
Finding the causative mutations constitutes the foundation for the study of 
pathogenetic mechanisms, which, in turn, is a prerequisite for developing specific 
therapies. Thus the hunt for the unidentified disease-causing variants in NM families will 
continue as new samples from NM families around the world are being sent to us for 
study. It is expected that novel pathogenic variants in the currently known NM genes 
will continue to be found with these new mutation detection methods. At the same time 
we are on the lookout for the next novel NM-causing gene. 
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